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ABSTRACT 
 
Anne Elizabeth Purfield:  A Mechanism of Resistance and Mode of Action for Drugs Against 
Plasmodium falciparum 
(Under the direction of Steven R. Meshnick, M.D., Ph.D.) 
 
     The need for new drugs to control widespread malaria caused by Plasmodium falciparum 
is critical.  Parasite resistance to currently used drugs is rampant and, in many cases, the 
drug’s mode of action and/or mechanism of resistance is unknown.  The three objectives of 
this dissertation address issues associated with resistance to the currently used antimalarial 
drugs, in addition to elucidating the mechanism of action of a novel antimalarial compound 
in development.   
     First, a real time PCR method was developed to distinguish parasite genotypes associated 
with mefloquine resistance in vitro.  Single nucleotide point mutations in the Plasmodium 
falciparum multi-drug resistance-1 (pfmdr1) gene are associated with mefloquine resistance 
in vitro.  This method may be applied to clinical malaria samples and used to predict 
treatment outcome as well as for surveillance of drug resistance.   
     In addition, the mechanism of action for the novel compound, [2,5-bis(4-amidinophenyl) 
furan], (DB75) was investigated.  DB75, the active metabolite of the oral pro-drug DB289, is 
a broad spectrum antiparasitic agent with impressive antimalarial activity both in vitro and in 
vivo.  It is currently in development for treatment of falciparum malaria, however the mode 
of action against falciparum parasites is unknown.  Results from ultraviolet confocal 
microscopy showed DB75 localization exclusively in the nucleus of parasites in culture.  
Further, microscopy studies using blood smears to distinguish morphologies suggested DB75 
 iv 
has a life stage-specific mechanism.  Parasites must be exposed during the ring stage for 
effective killing.  Finally, real time PCR gene expression assays suggested high 
concentrations of DB75 may alter the expression pattern in a manner consistent with the 
delay in maturation.  However, DB75 did not inhibit or enhance global nuclear transcription 
or developmental expression of six select genes.   
     The third objective was to determine potential synergistic interactions of DB75 in 
combination with current antimalarial drugs to determine a mechanism of action for DB75 
and to identify potential partner drugs for use in combination therapy with DB75.   
     Taken together, this work contributes to the arsenal of tools for surveillance of falciparum 
malaria drug resistance and partially elucidates a mechanism of action for a novel 
antimalarial diamidine that may be used for malaria therapy.   
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CHAPTER 1 
Introduction 
 
Geographical distribution of malaria 
     Malaria is a devastating disease caused by obligate intracellular protozoa of the 
Plasmodium genus.  Over 40% of the world’s population is at risk for developing malaria, 
and more than 1 million deaths are attributed to the disease annually (146).  There are four 
species of parasites that cause human malaria:  P. falciparum, P. vivax, P. malariae and P. 
ovale.  Although P. falciparum and P. vivax are the most frequent causes of malaria, P. 
falciparum is associated with most severe malaria infections and nearly all fatalities.  Sub-
Sarharan African children are most at risk; 18% of all deaths under the age of five years are 
attributed to malaria (130).   
     The geographical distribution of falciparum malaria is limited to that of its vector, 
Anopheles sp. mosquitoes.  The best vectors are in Sub-Saharan Africa, where 70% of 
clinical falciparum malaria cases occur in Africa (146) (Figure 1.1).       
Life cycle of P. falciparum 
     The life cycle of the malaria parasite is complex and has an integral role in the pathogenesis of 
malaria (Figure 1.2) (2, 37, 143).  The anopheles mosquito serves as the vector with the 
human serving as the host (2).  The parasite enters the human host as a sporozoite through the 
bite of a female anopheles mosquito.  It undergoes asexual reproduction in hepatocytes before 
entering the blood stream and rapidly invading erythrocytes as merozoites.  During a 48-hour 
period in the blood stream, the parasite matures from a merozoite to a trophozoite and finally to a 
multi-nucleated schizont.    
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     During the trophozoite stage, the parasite undergoes growth, developmental gene expression, 
protein production, hemoglobin digestion and finally, DNA replication.  The haploid DNA is 
replicated as the parasite advances to the multi-nucleated schizont stage.  At the final stage of the 
48-hour erythrocytic cycle, the multi-nucleated schizont ruptures the red blood cell, and new 
merozoites quickly invade uninfected erythrocytes.  New merozoites develop into the sexual 
stage gametocytes or maintain the asexual reproductive cycle by maturing into trophozoites to 
perpetuate the life cycle in the host.  The continuation of the asexual erythrocytic cycle causes 
malaria symptoms in the human host (Figure 1.2) (2, 37).  
     The asexual cycle is responsible for malaria morbidity and mortality, whereas the sexual stage 
is required for malaria transmission.  Female anopholes mosquitoes ingest blood meals prior to 
laying eggs.  When sexual-stage gametocytes are ingested, they travel to the mosquito midgut 
and undergo sexual fertilization to produce ookinetes.  Eventually the ookinetes mature into 
sporozoites and travel to the salivary gland of the mosquito.  Another human host is infected 
when the sporozoites are injected prior to the mosquito’s blood meal (2, 37).   
Clinical P. falciparum malaria presentation and diagnosis 
     Clinical malaria results from the continuation of the asexual erythrocytic cycle of the 
parasite in the human host (6).  Typical malaria disease includes a latent (asymptomatic) 
period followed by symptomatic disease.  The latent period can be as short as six days from 
the initial bite of an infected mosquito to clinical symptoms (17).  During the asymptomatic 
period, parasites replicate in hepatocytes after which they infect erythrocytes.  By the first 
asexual replication cycle in erythrocytes, infected individuals experience typical malaria 
paroxysms:  shaking chills followed by spiking fevers up to 106oF and finally, extreme 
sweating (6).   
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     The disease progresses differently among partially immune individuals and naïve 
individuals lacking protective immunity from repeated exposure.  Naïve individuals are more 
sensitive to parasitemia levels and experience febrile illness with as few as 10 parasites/µL of 
blood (148).  In contrast, individuals with partial immunity typically have a higher parasite 
threshold, accommodating up to 1000 parasites/µL of blood before onset of fever.  
Subsequently, patients with partial immunity experience a delay in the onset of typical 
symptoms associated with the high parasitemia in uncomplicated malaria such as:  headache, 
fatigue, abdominal pain, myalgia, nausea, diarrhea and irregular, but persistent fever  (61).   
     Malaria paroxysms may occur at regular intervals as the parasite population becomes 
synchronized.  High fever is thought to aid in synchronizing the parasites to a 48-hour cycle 
with coordinated schizont rupture and subsequent merozoite release (80, 81).  Since mature 
erythrocytic-stage schizonts release between 10 and 32 new merozoites, parasitemia 
increases about 10-fold every 2 days if left untreated (61).  Thus, parasitemia increases in a 
short period of time, and subsequent clinical complications associated with severe malaria 
appear 4-6 days after the onset of initial malaria symptoms (61).  Treatment within 6 days of 
the onset of the uncomplicated malaria symptoms can prevent severe malaria, and a full 
recovery may be expected within a few days (61).   
     Severe malaria may progress undetected from uncomplicated malaria, and the symptoms 
vary among adults and children.  Naïve individuals, such as African children, are most 
susceptible to severe malaria complications.  Children most often experience severe anemia 
with rare episodes of renal failure and pulmonary edema.  However, adults are more likely to 
experience renal failure and pulmonary edema (61, 136).  Typical symptoms of severe 
malaria, regardless of patient age, include thrombocytopenia (116, 145), respiratory distress 
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(94), acidosis (51, 116), or cerebral malaria which often leads to coma, convulsions and death  
(6, 38, 94, 102, 149).     
    The gold standard for malaria diagnosis is the identification of parasites in a Giemsa-
stained blood smear.  Thick and thin peripheral blood smears are used to assess the parasite 
density, species and disease severity (6, 142).  Other diagnostic methods include rapid 
antigen tests and polymerase chain reaction (PCR), but these have limitations due to cost, 
time and specificity (6). 
Mechanisms of action and resistance for antimalarial drugs 
    In the middle of the 20th century, health experts believed malaria could be successfully 
eradicated.  At the time, malaria had characteristics that made eradication seem possible,  
including the absence of an animal reservoir to harbor parasites and drugs that effectively 
cured infections to interrupt transmission (152).  Since that optimistic prediction, the 
characteristics of the parasite have changed.  Today, P. falciparum has developed resistance 
to nearly all antimalarial drugs in use (reviewed in (152, 172)).  Resistance to affordable 
drugs, such as chloroquine, is present in practically all areas endemic with falciparum 
malaria (reviewed in (152, 167, 172)) (Figures 1.1 and 1.3).  The rapid emergence and spread 
of antimalarial drug resistance has forced researchers to evaluate the antimalarial 
mechanisms of action and resistance in an effort to effectively treat patients to prevent 
escalation of the current situation with drug resistance (110).  
     The most widely used anti-malarial drugs are classified by their mode of action and 
structure.  The class of antimalarial compounds known as the antimetabolites include 
pyrimethamine, proguanil and sulfonamides.  The modes of action for these drugs are well 
established.  Antimetabolites inhibit the folate synthesis pathway enzymes dihydropteroate 
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synthase (DHPS) and dihydrofolate reductase (DHFR).  The folate pathway is necessary for 
pyrimidine synthesis by the parasite.  Mutations in the genes encoding the drug target, DHPS 
or DHFR, alter the binding affinity and reduce parasite sensitivity to the drug (37).  The 
mutations are used as molecular markers for decreased parasite susceptibility to 
antimetabolites (166).      
     For many antimalarials, the modes of action as well as the mechanisms of resistance 
remain unknown in spite of effective chemotherapeutic properties.  This is the case for 
artemisinin derivatives and quinoline-containing drugs, which include chloroquine, 
mefloquine, halofantrine and amodiaquine (reviewed in (88, 91, 110). 
     The peroxide, artemisinin, is a relatively new antimalarial derived from Artemisia annua, 
in the Asteraceae plant family (173).  Artemisinin is the parent compound of derivatives 
synthesized to improve administration by oral, rectal and parenteral routes (reviewed in 
(173)).  Multiple mechanisms of action have been proposed for artemisinin compounds, 
including drug interaction with heme to form toxic free radicals and inhibition of the parasite 
sarcoplasmic endoplasmic reticulum ATPase  (49, 101, 156).  The latter theory is supported 
by evidence that mutations in the putative ATPase target can alter artemisinin susceptibility 
of parasites in culture (156).  However, there is currently no evidence for in vivo resistance 
(173).  
     Chloroquine is a synthetic 4-aminoquinoline compound with an unknown mechanism of 
action.  Chloroquine was the first antimalarial synthesized and is still used today because of 
its cost-effectiveness (110).  Despite its widespread use and 70+ year history, the mechanism 
of chloroquine action is not fully understood (71, 110).  Although the killing mechanism is 
debated, there is some agreement that the drug targets the parasite food vacuole.            
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     Chloroquine, a weak base, accumulates in the parasite food vacuole and alters the pH of 
the acidic organelle (176).  In the parasite food vacuole, enzymes digest hemoglobin into 
heme (ferriprotoporphyrin IX), which is toxic to the parasite.  Heme is detoxified via 
biocrystallization into hemozoin, and disruption of the process that converts hemoglobin to 
heme to hemozoin has detrimental effects on the parasite (27).  Chloroquine binds heme and 
interrupts the heme polymerization process, and the resulting heme-chloroquine complex is 
toxic (55, 150).   
     Further evidence that the food vacuole is an important chloroquine target was provided by 
the recognition that mutations in the pfcrt gene, which encodes the Plasmodium falciparum 
chloroquine resistance transporter, confer decreased susceptibility to chloroquine (54).  Pfcrt 
is a transmembrane protein on the surface of the food vacuole (54).  Single nucleotide point 
(SNP) mutations in pfcrt results in amino acid substitutions in Pfcrt, and allow leakage of 
chloroquine out of the food vacuole, mitigating its effect on vacuolar pH and its ability to 
prevent hemozoin synthesis  (71, 131, 132, 141, 161).  Although the specific role of Pfcrt in 
drug susceptibility remains unresolved, twenty mutations in the pfcrt gene have been 
associated with decreased in vitro chloroquine sensitivity (31).  Only one mutation, resulting 
in a change from lysine to threonine at amino acid 76 (Lys76 → Thr76), has been linked to 
clinical treatment failure with chloroquine (Table 1.1).  The Thr76 substitution is used as a 
molecular marker for chloroquine resistance.  Removal of the Thr76 mutation by allelic 
exchange restores in vitro sensitivity in parasites and confirms the importance of this 
mutation in chloroquine sensitivity (83).   
     Another gene thought to be associated with drug resistance is pfmdr1.  pfmdr1 encodes the 
parasite food vacuole transport protein, P-glycoprotein homologue 1 (Pgh1), which is a 
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homologue of the human P-glycoprotein, encoded by human multi-drug resistance-1 
(MDR1).  Human P-glycoproteins modulate susceptibility to multiple drugs in mammalian 
cells (73, 128).   
     Mutations in pfmdr1 are associated with altered parasite susceptibility to multiple drugs, 
including chloroquine and mefloquine (35).  A pfmdr1 SNP resulting in an amino acid 
substitution (Asn86 → Tyr86) in Pgh-1 was found to be associated with chloroquine treatment 
failure in patients (Table 1.1) (42).  However, other studies show that while the Asn86 → 
Tyr86 substitution in pfmdr1 is correlated with increased susceptibility to chloroquine in vitro, 
it is associated with decreased susceptibility to mefloquine (114).   
     Mefloquine, an aryl amino alcohol compound, has been very effective as an antimalarial.  
The drug has a long terminal half-life, which makes it an ideal candidate for prophylaxis, 
because one dose can protect for a week.  However, the long half life has also led to the rapid 
development of resistance when used in endemic areas for falciparum malaria treatment (37, 
163).   
     Although the mefloquine mechanism of action has not been elucidated, multiple 
mechanisms of resistance have been described.  Multiple SNPs in pfmdr1 are associated with 
decreased parasite susceptibility to mefloquine (Table 1.1) (33, 118).  Also, increased copies 
of  pfmdr1 in the falciparum genome are correlated with decreased mefloquine susceptibility 
(118, 120).  Taken together, these observations suggest a role for pfmdr1 in drug 
susceptibility.  
pfmdr1 is a modifier of drug susceptibility 
     Since its discovery, pfmdr1 has been used as a marker of parasite susceptibility to 
structurally diverse antimalarials, including chloroquine, a 4-aminoquinolone and aryl amino 
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alcohols, such as mefloquine, quinine and halofantrine, quinine, and lumafantrine (124).  The 
Pgh1 product of pfmdr1 is thought to regulate intracellular drug or substrate concentrations 
(33).  Therefore, pfmdr1 gene amplification or structural modifications to Pgh1 via mutations 
are likely to affect intracellular drug concentrations and parasite susceptibility.     
     To link pfmdr1 gene amplification with a physiological mechanism of drug resistance, 
pfmdr1 copy number was assessed with transcript levels (170, 171).  A mefloquine resistant 
P. falciparum strain contained more copies of the pfmdr1 gene as well as pfmdr1 mRNA 
transcripts (170, 171).  Further, Rohrbach, et al., correlated increased pfmdr1 copy number 
with Pgh1 protein expression and function in vitro (126).  Using a fluorescent substrate, 
Rhorbach, et al., found that Pgh1 acts as a transporter for substrates into the food vacuole 
(126).  This supports the theory that Pgh1 regulates substrate concentrations in the food 
vacuole, suggesting that modifications of the gene copy number or protein structure may 
directly affect intracellular drug distribution (126).  The correlation between gene copy 
number, transcript levels and protein levels has been difficult to show in clinical samples 
because large quantities of freshly harvested parasites are required to obtain adequate mRNA 
and protein for analysis.   
     In epidemiological studies, pfmdr1 amplification correlates with resistance to multiple 
antimalarials.  Therefore, increased pfmdr1 gene copy number is considered a molecular 
marker for resistance to antimalarials, including mefloquine, quinine, halofantrine and 
lumafantrine (4, 170).  In laboratory strains and clinical isolates, there is a correlation 
between in vitro mefloquine resistance and resistance to halofantrine, lumafantrine and 
quinine, suggesting the drugs may have a similar mechanism of resistance, such as increased 
pfmdr1 copy number (34, 58, 108, 111, 164, 171).   
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     SNPs in pfmdr1 are additional molecular markers for mefloquine resistance in parasites, 
providing further evidence that pfmdr1 is important for resistance. Extensive sequencing of 
P. falciparum isolates revealed nonsynonymous point mutations resulting in codon changes 
at 5 positions (Figure 1.4) (56).  The five key amino acid substitutions are:  Asn86 → Tyr86, 
Tyr184 → Phe184, Ser1034 → Cys1034 and Asn1042 → Asp1042, Asp1246 → Tyr1246 (Figure 1.4 and 
Table 1.1).  These mutations were first noted in studies of the role of pfmdr1 in chloroquine 
resistance in vitro (56).  Further in vitro studies showed a correlation between one or more of 
these SNPs and resistance to additional antimalarials with laboratory strains (56, 111, 124, 
157, 160).   
     Assessments of malaria patient samples for an association between decreased drug 
susceptibility and mutations revealed discordant findings (47, 48, 75, 99, 114, 120).  For 
example, Wilson et al., found no association between these previously described 5 alleles 
(Table 1.1) and decreased susceptibility to mefloquine and halofantrine in clinical samples 
(171).  In contrast, Duraisingh, et al. showed a correlation between increased susceptibility to 
mefloquine and chloroquine and the presence of the pfmdr1 Tyr86 mutation (47).  Finally, the 
amino acid substitution at Phe184 was associated with decreased mefloquine susceptibility in 
work by this author (114). These conflicting reports suggest additional factors may contribute 
to drug sensitivity in vitro.  
     When pfmdr1 allelic variants were assessed with respect to patient outcome, results were 
often inconsistent and varied geographically (Table 1.2).  This may be due, in part, to the 
distribution of the mutations in parasite populations.  For instance, Tyr86 and Phe184 mutations 
have been found in Asia, Africa and South America.  In contrast, mutations at amino acid 
positions 1034, 1042 and 1246 are most prevalent in South America (reviewed in (174)). 
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Factors such as variable rates of transmission and drug pressure may influence the 
geographical distribution of parasite genotypes (174). 
     Taken together, studies to date have failed to conclusively identify SNPs in pfmdr1 as a 
mechanism of antimalarial resistance and treatment failure; however the high prevalence of 
these mutations and the associations with drug resistance and treatment failure cannot be 
dismissed entirely.  Additional studies with larger numbers of samples from geographically 
diverse settings are needed.  In Chapter 2 of this thesis a new real time PCR method for 
assessing pfmdr1 genotype directly from patient blood is presented.  This method is 
amenable for high-throughput analysis of large numbers of samples, which would better 
define an association between SNPs and drug susceptibility.   
Molecular surveillance of antimalarial drug resistance  
     As antimalarial resistance emerges de novo and spreads rapidly with disease transmission, 
it is increasingly important to use surveillance tools to monitor drug susceptibility in parasite 
populations.  The gold standard for monitoring drug efficacy is assessing clinical treatment 
outcome.  A more timely method for surveying resistance is to examine parasite 
susceptibility to antimalarials in vitro (29, 140).  The data collected in vitro may predict 
impending drug resistance in patients (23, 127).   
     Molecular markers for drug resistance are an additional tool for surveillance of drug 
susceptibility.  The prevalence of  molecular markers associated with drug resistance will 
yield insight into the evolution of parasite genotypes and the spread of resistance between 
geographical regions (72, 106).   
     Assessment of drug susceptibility and molecular markers provide insight about the 
temporal evolution and geographical spread of parasite populations exhibiting drug resistance 
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(140).  Healthcare officials evaluate all available surveillance data to adjust policy regarding 
antimalarial treatment.  Proper action in a timely manner will thwart the spread of 
antimalarial drug resistance, prolong the use of treatments and ultimately, reduce mortality.   
Artemisinin combination therapy to prevent resistance 
     Because drug resistance develops quickly, the World Health Organization (WHO) 
recommends the use of drug combination therapy (1, 50).  The basis for combination therapy 
incorporates multiple antimalarial drugs with indifferent or synergistic effects when used in 
combination for parasite inhibition (168).  Ideal candidates for combination therapy exhibit 
independent modes of action and unique biological targets (1, 168).  Further, drugs with 
similar pharmacokinetic profiles or plasma half-life will be eliminated at the same rate.  
Simultaneous elimination of multiple drugs ensures the parasite is not exposed to sub-
therapeutic levels of a single drug as with monotherapy.  With monotherapy, sub-therapeutic 
levels of a the partner drug alone promotes selection for resistant parasites because the drug 
concentration is too low to eliminate the parasite population (64). 
     Currently, one candidate for use in combination therapy is artemisinin and its derivatives:  
artesunate, dihydroartemisinin and artemether.  When used as monotherapy in a 3-day 
treatment regimen, artemisinin has an incomplete cure rate (~50%) with no clinical evidence 
of resistant parasites (reviewed in (100)).  However, artemisinin compounds used in 
combination therapy with partner drugs for 3-day dosing regimens are highly effective and 
are the current preferred basis for combination therapy (1, 23, 119).  Artemisinins have short 
plasma half-lives; combining artemisinin with a partner drug that has a longer plasma half 
life will ensure long suppressive treatment after the initial rapid decrease in parasitemia from 
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artemisinin, however this is a conundrum, since it potentially promotes emergence of 
resistant parasites to the longer-acting partner drug (reviewed in (173), (1, 64)).   
     The pharmacokinetics of artemisinin combination therapy could allow for resistance to the 
longer acting partner drug to develop.  Once artemisinin is rapidly eliminated, the partner 
drug will be present in sub-therapeutic levels in the patient plasma  The low levels of 
parasites that may exist in the patient may develop resistance to the longer acting partner 
drug that is, essentially, monotherapy at this point (68).  However, the effect of artemisinin 
combination therapies with mismatched pharmacokinetic profiles on the selection of resistant 
parasites to the partner drug has yet to be determined in patients, and artemisinin in 
combination remains the preferred therapy (1, 79).  Additional clinical trials and in vitro 
susceptibility testing are needed to monitor the effects on developing resistance to 
artemisinin and partner drugs with longer plasma half lifes.  
A need for new antimalarial drugs 
    There is an increasing need for new antimalarial drugs to use for combination therapy 
against malaria.  With the exception of artemisinin compounds, all currently available 
antimalarials have been used as monotherapy, and resistant parasites have been detected in 
patient isolates (9).   
     Another factor driving the need for new antimalarials is cost per treatment.  Drugs 
developed through public-private partnerships will be more affordable than those developed 
by pharmaceutical companies that focus development of antimalarials for the population 
needing prophylaxis, such as travelers visiting or working in endemic regions (9).  In 
addition to reduced cost, new drug entities used for combination therapy may offer another 
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advantage.  Chemical entities that have not been previously used for monotherapy to treat 
malaria may last langer in the absence of pre-existing resistance (1).   
Aromatic diamidines have antimalarial activity 
     Pentamidine, [1,5-di(4-amidinophenoxy)pentane] (Figure 1.5a), a dicationic diamidine, 
has been used for clinical treatment of protozoan infections such as leishmaniasis and Human 
African trypanosomiasis (HAT) (165).  Pentamidine also has activity against Plasmodium 
falciparum, however the drug is not orally bioavailable and has considerable side effects, 
including renal toxicity and cardiotoxicity (5, 21, 52).  Therefore, pentamidine has been 
passed over as a potential malaria therapeutic in favor of drugs with oral bioavailability and 
fewer side effects (21).  In spite of the side effects and need for parenteral administration, it 
is still a first line treatment for early-stage HAT and a second line drug for antimony-resistant 
visceral leishmaniasis and Pneumocystis jiroveci pneumonia (PCP) (21, 165).  The synthesis 
of new pentamidine structural analogues for alternative treatments of HAT has introduced a 
class of broad-spectrum antimicrobials with orally active prodrugs lacking the side effects 
associated with pentamidine (13, 122).  This class of aromatic diamidines inspired by 
pentamidine is being investigated for therapeutic use for malaria, PCP and leishmaniasis, in 
addition to HAT (13, 165). 
Diamidine mechanisms of action for antimicrobial activity 
     The mechanism of action of pentamidine and diamidine compounds in general remains 
unknown (21).  Studies have provided multiple theories for the selective inhibitory action of 
diamidines in a variety of protozoan, including Giardia lamblia, trypanosomes and P. 
falciparum.  These include DNA-binding and inhibition of replication enzymes (7, 11, 13, 
98), collapse of mitochondrial membrane potential and subsequent cellular respiration 
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inhibition (86, 158), heme binding (147),  inhibition of peptidase activity (103) and 
disruption of calcium homeostasis through acidocalcisome localization (14).  These 
investigations suggest pentamidine may have multiple biological targets across a broad range 
of protozoan (133).   
     Pentamidine is the diamidine most studied, however mechanistic studies of pentamidine 
in Plasmodium are limited.  Pentamidine has clear antimalarial activity with a half-maximal 
inhibitory concentration (IC50) value comparable to those of standard antimalarial agents 
(13, 147).  One debated mechanism of action for pentamidine in Plasmodium is the inhibition 
hemozoin formation in the parasite food vacuole.  When added to parasite lysate in vitro, 
pentamidine binds the toxic heme (ferriprotoporphyrin IX) molecule that is produced during 
hemoglobin metabolism.  By binding heme, pentamidine inhibits the parasite’s ability to 
crystallize the molecule into a nontoxic form, hemozoin (147).  Pentamidine and chloroquine 
exhibit similar binding affinities for heme (Kd=2.9µM and 2.5µM, respectively) (147, 150).  
Structurally similar diamidines with antimalarial activity, including propamidine and 
stilbamidine, were also found to bind heme in the presence of parasite lysate at 
concentrations in the micromolar range, suggesting additional diamidines may bind heme as 
well (147).       
     The uptake and transport of pentamidine has also been studied to determine the 
mechanism of action.  Pentamidine is taken up by parasite-infected red blood cells, but not 
by uninfected red blood cells.  Investigations using tritiated pentamidine show drug 
concentrations in parasite-infected cells are 500-fold greater than in the extracellular media 
within three hours of drug exposure (147).   
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     It has been suggested that pentamidine is transported across the erythrocyte membrane by 
the new permeation pathway (NPP), also known as the plasmodial surface anion channel 
(147).  Parasite-infected erythrocytes transport a broad range of solutes across the host cell 
membrane through pores, collectively referred to as the NPP (78). It is unknown whether the 
channel is composed of parasite-produced proteins exported to the erythrocyte membrane or 
erythrocyte proteins that are remodeled to form the pores of the NPP (76).  The NPP is 
believed to primarily function as an anion channel, however permeability to cations and 
nonelectroytes has been noted (76-78, 147).  The destination of solutes transported by the 
NPP is unknown.  The NPP may deposit solutes into the erythrocyte cytoplasm or into the 
tubovesicular membrane, which is a network of tubular membranes connecting the 
erythrocyte membrane directly to the parasitophorous vacuole membrane (40, 87).  Inhibitors 
of the NPP block pentamadine uptake by the parasite-infected red blood cell, suggesting a 
role for the NPP in drug transport (147).   
     In addition to heme binding, pentamidine and other diamidine compounds bind nucleic 
acids.  Dicationic diamidine compounds, including pentamidine, bind to the minor groove of 
DNA with an affinity for AT-rich sequences (11, 179).  This attraction  is facilitated by the 
electrostatic interaction between the positively-charged diamidine molecule and the 
negatively charged nucleic acids (98).  Plasmodium, as well as leishmania and trypanosomes, 
contain abundant AT rich nucleic acid sequences, suggesting diamidine compounds may be 
particularly effective against these organisms if nucleic acid-binding is a mechanism of 
action (8, 57, 93).  
     DNA binding affinity is associated with biological activity of diamidines in protozoa and 
tumor cells (11, 32, 85).  DNA binding affinity is directly correlated to DNA topoisomerase 
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II inhibition in Giardia lamblia in vitro (12, 19).  Inhibition of DNA topoisomerase II is 
believed to inhibit nuclear DNA synthesis and may serve as the mechanism of killing for 
dicationic diamidines in G. lamblia (12).   
     Subcellular localization studies show diamidine compounds localize to the nucleus of 
trypanosomes and tumor cells, further suggesting nucleic acids may be a target in the cell 
(85, 97).  Nuclear localization is dependent on the structure of diamidine compounds and 
compounds with higher affinity for binding DNA are more likely to localize to the nucleus 
(85, 105).   
DB289 is the orally active prodrug of the novel antimicrobial agent, DB75 
     New dicationic diamidines were synthesized in an effort to improve oral bioavailability 
and reduce toxicity associated with pentamidine.  DB75, [2,5-bis(4-amidinophenyl)furan] 
(Figure 1.5b), also known as furamidine, has impressive activity against a broad range of 
microbes, including P. falciparum.  In some models, DB75 shows improved antimicrobial 
activity with reduced toxicity over pentamidine (19, 122, 129).  However, DB75 has poor 
oral activity when administered alone (180).  The positively charged cationic moieties of 
DB75 may prevent drug transport across the intestinal epithelium (182).  To use DB75 as a 
clinical therapeutic, an orally active pro-drug was synthesized.  The pro-drug, DB289, [2,5-
bis-(4-amidinophenyl)furan bis-O-methylamidoxime], may be administered orally and is 
metabolized to the active form, DB75 (Figure 1.5c) (180, 181).  The biotransformation 
process of DB289 to DB75 in the human liver consists of three O-demethylation reactions 
catalyzed by the Cyp4F enzyme subfamily and three N-dehydroxylation reactions catalyzed 
by cytrochrome b5 and NADH-cytochrome b5 reductase  (135, 162).          
 18 
     DB289 is currently the lead diamidine compound for therapeutic treatment against HAT, 
PCP and malaria (personal communication, Richard R. Tidwell).  The pro-drug is in Phase 
III clinical trials for treatment of acute HAT and PCP.  DB289 is in Phase II clinical trials for 
both prophylaxis and treatment of acute, uncomplicated P. vivax and P. falciparum malaria 
(personal communication, Richard R. Tidwell).  No serious adverse side effects were 
observed in human clinical trials for either HAT or PCP (177). For the treatment of HAT, 
DB289 has achieved a 95% cure rate (personal communication, Richard R. Tidwell).    
     The pro-drug has an impressive 96% (22 of 23 patients) cure rate for acute uncomplicated  
falciparum malaria when used as monotherapy (100mg, twice daily for 5 days) to treat 
patients in a Bangkok, Thailand (178).  No serious adverse side effects were noted, and 
DB289 has proceeded to Phase IIb clinical trials to determine the ideal treatment regimen in 
malaria.  The efficacy of DB75 is also being studied in combination therapy with artesunate, 
an artemisinin derivative (personal communication, Richard R. Tidwell).   
     Despite the high efficacy of DB289 in patients, the mechanism of action of DB75 is 
unknown.  Chapter 3 of this dissertation will address the mechanism of action for DB75 in P. 
falciparum.      
Dissertation objectives and significance 
     This dissertation work examines mechanisms of resistance in P. falciparum and the mode 
of action for the novel diamidine, DB75.  The major objectives of this dissertation were 1) to 
develop real time PCR methods to evaluate genotypic differences in drug resistant parasites 
from clinical samples; 2) to investigate the mechanism of action for DB75 in P. falciparum in 
vitro; and 3) to identify potential therapeutic partners for DB289 through drug combination 
studies in vitro.   
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     First, a new method for high throughput analysis of parasite mutations associated with 
drug resistance will advance the field of malaria drug surveillance.  Identification of drug 
resistant parasite populations in advance of clinical trials will expedite policy changes 
regarding treatment regimens.   
     Second, identification of the DB75 mechanism of action will have important implications 
for the clinical use of DB289 as well as other dicationic diamidines in development for a 
similar use.  The mechanism will determine how DB289 may be best used in combination 
therapy to avoid development of resistance.  Further, the mode of action will be used to 
determine how parasite resistance will develop against DB289. 
     Finally, the evaluation of DB75 in combination with other antimalarial agents in vitro will 
yield a greater understanding of the drug’s mechanism of action against P. falciparum.  In 
addition, these combination studies will determine how parasite inhibition is affected by 
DB75 in the presence of a second drug.  Potential partner drugs for combination therapy may 
be identified through these interactions 
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Figure 1.1:  Geographic distribution of P. falciparum malaria risk.  Global risk of 
transmission is shown with intensity of green color. The darkest green indicates 
hyperendemic or holoendemic regions.  Global distribution of drug resistance from sentinel 
sites to 2004  (146).  
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Figure 1.2:  Life cycle of the P. falciparum parasite.  The plasmodium parasite has a 
complex life cycle between the human host and the mosquito vector.  This includes the 
sporogenic cycle in the mosquito and both the liver and erythrocytic cycles in the human 
host.   
Source:  Centers for Disease Control and Prevention: (http://www.dpd.cdc.gov). 
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Figure 1.3:  Worldwide distribution of P. falciparum drug resistance.  Decreased 
susceptibility to chloroquine (pink triangle), sulfadoxine-pyramethamine (green circle), and 
mefloquine (yellow star) is widely reported in areas of high malaria transmission (shaded) 
(50). 
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Figure 1.4:  Model of P-glycoprotein homologue-1 protein encoded by pfmdr1.  The 
model shows 12 predicted transmembrane domains for this transport protein with locations of 
single nucleotide polymorphisms and resulting amino acid changes (45). 
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Table 1.1:  Important mutations associated with decreased antimalarial susceptibility 
 
Gene Gene Product Important amino acid 
substitutions 
Associated Decreased 
Drug Susceptibilitya 
pfcrt Plasmodium falciparum chloroquine 
resistance transporter Lys
76
 to Thr76 Chloroquine 
      
pfmdr1 P-glycoprotein homologue 1 Asn86 to Tyr86 
Mefloquine, Halofantrine, 
Lumafantrine, Quinine, 
Chloroquine 
  Tyr184 toPhe184 Mefloquine, Halofantrine, Lumafantrine, Quinine 
  Ser1034 to Cys1034 Mefloquine, Halofantrine, Lumafantrine, Quinine 
  Asn1042 to Asp1042 Mefloquine, Halofantrine, Lumafantrine, Quinine 
  Asp1246 to Tyr1246 Mefloquine, Halofantrine, Lumafantrine, Quinine 
 
a Determine by in vitro susceptibility testing
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Table 1.2:  Pfmdr1 single nucleotide polymorphisms resulting in amino acid 
substitutions in Pgh-1 are geographically linked to antimalarial treatment failure in 
clinical studies 
 
Drug Southeast Asiaa Sub-Saharan Africab 
Mefloquine 
No correlation (115)  
Tyr86 (114) 
Phe184 with Cys1034 or 
Asp1042 (114) 
Phe184 (75) 
 
Chloroquine Tyr
86
 with pfcrt Lys76 (16) 
Tyr86 (42) 
Tyr86 (44, 46, 47, 109) 
No Correlation (63) 
Tyr86 with pfcrt Lys76  (109, 154) 
Amodiaquine  
Tyr86 (43, 46, 62, 66) 
Tyr1246 (43, 66) 
Tyr86/ Tyr184/ Tyr1246 (66, 67) 
Artemether-
Lumafantrine 
(Coartem) 
 Phe184 (144) 
Amodiaquine-
Artemisinin  
Tyr86(107) 
Tyr1246 (66, 107) 
 
a
 Single nucleotide polymorphisms correlated with antimalarial drug resistance in Southeast 
Asia 
b
  Single nucleotide polymorphisms correlated with antimalarial drug resistance in Africa 
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Figure: 1.5:  Chemical structures of dicationic diamidines with antimalarial activity.  a) 
Pentamidine [1,5-di(4-amidinophenoxy)pentane]; b) DB75 [2,5-bis(4-amidinophenyl)furan]; 
c) DB289 [2,5-bis(4-amidinophenyl)furan bis-O-methylamidoxime] 
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PREFACE 
 
     This chapter was published in Malaria Journal in 2004 under the same title:  A New 
Method for Detection of pfmdr1 Mutations in Plasmodium falciparum DNA Using Real 
Time PCR   (121).  Additional contributing authors include:  Amy Nelson, Anita 
Laoboonchai, Kanungnij Congpuong, Phillip McDaniel, R. Scott Miller, Kathy Welch, 
Chansuda Wongsrichanalai and Steven R. Meshnick.   
     I contributed to this work through the design of the real time PCR assay and analysis of 
parasite DNA samples with real time PCR and standard PCR.  The primary author is also 
responsible for data analysis, including statistics and the preparation of the manuscript for 
publication.  
     For publication in this dissertation minor changes were made to this article.  These 
changes do not alter the conclusions drawn by the authors at the time of the original 
publication.  Changes include:   
• Discussion Section was enhanced 
• Table 2.3:  Two samples are described as 184Phe (mutant) in post-culture DNA but 
184Phe and 184Tyr (mixed infection) in DNA extracted directly from patient blood. 
• Table 2.4:  The specificity of real time PCR for detecting Asp1042 is 95% (60/63) 
       The results from epidemiology studies related to these samples evaluated by real time 
PCR are included in Nelson, et al., 2005, and Pickard et al., 2003, (104, 114). 
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CHAPTER 2 
A New Method for Detection of pfmdr1 Mutations in Plasmodium falciparum DNA Using 
Real Time PCR 
Introduction 
     The increasing prevalence of multi-drug resistant parasites threatens to impede efforts to 
control malaria world-wide (172). Current in vitro and in vivo methods to monitor the 
emergence of drug resistance are difficult, costly and labor-intensive. Molecular methods 
could prove to be useful alternatives (117). 
     For Plasmodium falciparum, the pfmdr1 gene product, Pgh1, is thought to play an integral 
role in the mechanism behind parasite resistance to multiple malarial drugs (124). Both 
increased gene copy number and SNPs have been associated in epidemiological studies with 
changes in sensitivity to chloroquine and mefloquine (reviewed in (152, 166, 172)). In two 
studies from South-east Asia, both increased pfmdr1 gene copy number and SNPs have been 
associated with in vitro resistance to mefloquine (114, 118).  The allelic variation of pfmdr1 
and its association with drug resistance is geographically varied.  For instance, Tyr86 and 
Phe184 mutations have been found in Asia, Africa and South America.  Contrary, mutations at 
amino acid positions 1034, 1042 and 1246 are most prevalent in South America (reviewed in  
(174)). The molecular physiology of these point mutations has not been elucidated, however 
epidemiological evidence suggests a strong association between their existence and drug 
sensitivity (174).  The extent of the significance of pfmdr1 allelic variations as molecular 
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markers of drug resistance may be better discerned using temporal and geographical data 
collected from surveillance of parasite populations (140).  With adequate surveillance data, 
healthcare officials may evaluate and adjust antimalarial treatment policy as necessary.  On 
an individual basis, a rapid detection method could be used to predict treatment outcome and 
the appropriate antimalarial regimen may be administered.    
     A real-time PCR assay has been developed for the rapid detection of pfmdr1 SNPs. This 
assay was developed to be used in conjunction with a previously developed assay for pfmdr1 
gene copy number (114) to assess molecular markers as predictors of mefloquine failure in a 
clinical study that took place in Sangkhlaburi, Thailand, in 2001–2.  
     Numerous studies have shown discrepancies between in vitro and in vivo tests for 
antimalarial drug resistance (125, 138, 151). In order to understand why, pfmdr1 genotypes 
were determined directly from patient blood and from cultures derived from those patients 
and compared. 
Materials and Methods 
Patient samples 
     This study received ethical approval from the University of North Carolina IRB and the 
Thai Ministry of Public Health. Patients presenting with slide-confirmed falciparum malaria 
to the free Ministry of Public Health malaria clinic or the Kwai River Christian Hospital 
clinic in Sangklaburi, Thailand from during July 2001 – August 2002 were enrolled. Patients 
with vivax infections, history of anti-malarial drug use within the past two weeks, bleeding 
tendency (by self-reported history or based on medical records), or severe/complicated 
malaria requiring prompt medical management for life support were excluded. In total, 74 
patients consented. Blood samples were taken, aliquoted, stored in liquid nitrogen, and 
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transported to the Armed Forces Research Institute for the Medical Sciences (AFRIMS) in 
Bangkok. At AFRIMS, aliquots were thawed for in vitro culture. 59 of the 74 patient blood 
samples were successfully cultured as previously described (Figure 2.1) (114, 155). Parasites 
were cultured for between 2 and 188 days (mean = 38.5; median = 23). DNA was extracted 
from patient blood ("pre-culture") and cultured parasites ("post-culture") using the QiaAmp 
DNA Blood Minikit Blood and Body Fluid Spin Protocol (Qiagen, Valencia, CA) and then 
shipped on dry ice to the University of North Carolina. 
Standard PCR 
     DNA was PCR-amplified using a MJ Thermocycler (MJ Research, Waltham, MA) as 
previously described (114). DNA sequencing was performed at the University of North 
Carolina Sequencing Core facility using a 3100 Genetic Analyser (Applied Biosystems, 
Foster City, CA). The sequencing reaction was done using the ABI PRISM™ BigDye™ 
Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq® DNA Polymerase, FS 
(Applied Biosystems). 
Real-time PCR   
     For real-time PCR, pre-culture DNA and post-culture DNA were genotyped using an 
Applied Biosystems Prism 7000 Sequence Detection System (Applied Biosystems). This 
assay uses sequence-specific fluorescently-labeled minor groove binder (MGB™) probes to 
distinguish SNPs (3, 65, 90). Primers and probes (Table 2.1) were designed using Primer 
Express Software, Version 2.0 (Applied Biosystems). Primers were obtained from Qiagen. 
Fluorescent MGB™ probes were produced by Applied Biosystems and labeled with reporter 
dyes, 6FAM or VIC, at their 5' ends and non-fluorescent quencher molecules at their 3' ends. 
Primer and probe concentrations were optimized according to the TaqMan Universal PCR 
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Master Mix technical bulletin (Applied Biosystems) using DNA obtained from P. falciparum 
strain 3D7 or from patient specimens. 300 nM of both forward and reverse primers were 
found to be optimal for all SNPs. Optimal probe concentration was determined to be 250 nM 
for all MGB probes used in this study. Using 10-fold serial dilutions of 3D7 genomic P. 
falciparum DNA, as few as 8 copies (0.001 ng) of genomic P. falciparum DNA could be 
detected.  
     Each real-time PCR amplification reaction contained both the wild type probe labeled 
with FAM, and the mutant probe labeled with VIC. Presence of either SNP could be imputed 
from the relative increase of fluorescence of the two fluorophores (Figure 2.2).  Mixed 
infections were detected by the increase of fluorescence from both flurophores.  All reactions 
were done in duplicate. 
Parasite culture 
     Of the 74 patients enrolled, parasites were successfully cultured from 59. Following 
treatment, 20 of the 74 admission patients recrudesced. Parasites were successfully cultured 
from 13 of these 20 recrudescent patients (Figure 2.1). 
Results 
Real-Time PCR is sensitive and specific   
     The sensitivity and specificity of SNP detection using real-time PCR were measured in 22 
post-culture DNA samples using DNA sequencing as the gold standard (Table 2.2). Nineteen 
cultures were derived from blood of patients upon admission to the study. The other three 
cultures were obtained from those who failed treatment. Two samples contained mixtures of 
SNPs at single positions based on DNA sequencing. Of the 20 monoclonal samples, 19 were 
concordant for all pfmdr1 SNPs when analyzed using both methods. The discordant sample 
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was not an artifact since both the real-time PCR and sequencing reactions gave identical 
results when repeated. The discordant sample contained a single discrepancy at position 184 
(phenylalanine by sequencing and tyrosine by real-time PCR). Thus, the sensitivity of real-
time PCR method to detect Tyr86 or Asp1042 SNPs was 100% and the sensitivity to detect 
Phel84 was 92%; there were no Cysl034 mutations detected. Real-time PCR was 100% specific 
for each mutation. The sensitivity and specificity of the assay to detect all four SNPs were 
94% and 100%, respectively. 
     Two of the 22 samples were found to be mixed infections when sequenced. One sample 
contained a mixture of Tyrl84 and Phel84. The other sample contained a mixture of Asn86 and 
His86. The real-time PCR method accurately identified the Tyrl84/Phel84 mixed population. 
However, because the probes were designed to detect only Asn86 or Tyr86, His86 was not 
detected by real-time PCR. 
Comparison of SNPs in paired pre- and post-culture DNA 
     In order to determine how the process of culturing parasites in vitro alters genotype, a 
comparison was made between the pfmdr1 genotypes of DNA extracted from pre-and post-
culture parasites as measured by real-time PCR. Of the paired pre- and post-culture 
specimens, both members of 68 pairs were successfully amplified by real-time PCR. Fifty-
eight of these pairs were obtained from admission patient blood while 10 pairs were derived 
from recrudescent patients. 
     Fifty-eight of the pre-culture genotypes were monoclonal, nine pre-culture samples had 
mixtures of alleles at single positions, and one had mixed SNPs at two positions (184 and 
1042). Table 2.3 shows the number of isolates with specific combinations of pfmdr1 
genotypes pre- and post-culture at each specific locus. Isolates with identical genotype at 
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each locus before and after culture are enumerated in the shaded diagonal. Overall, 54 of 68 
(79%) pre-culture DNA samples were completely concordant with post-culture DNA at all 
four polymorphic sites examined. While there was a wide variation in the length of time 
parasites were cultured before DNA was extracted, there was no correlation between 
genotype discordances and length of time in culture (data not shown). Five of the 14 
discordant isolates exhibited single differences at position 184, and two were different at 
position 1042. Seven discrepant samples contained mixtures of alleles at one or more sites 
before and/or after culture. Six samples showed a mixture of alleles pre-culture and single 
alleles post-culture. This type of selection occurred at amino acid 184 for four isolates, and 
1042 for two isolates. Two of these six also had changes at a second position, amino acid 86. 
Finally, one of the seven samples was monoclonal at amino acid 184 pre-culture but 
polyclonal post-culture (and also exhibited a change from Asn to Asp at 1042).   
     There was no correlation between discordant samples and selection for the mutant 
genotypes associated with the drug resistant phenotype.  Seven of the 14 discordant samples 
resulted in the wild type genotypes after isolates were cultures.  The remaining 7 discordant 
isolates contained mutant genotypes following culture.   
Novel His86 mutation identified 
     In one DNA culture sample neither wild type nor mutant probes revealed amplification 
during real-time PCR. This post-culture sample was amplified by standard PCR methods and 
sequenced to genotype the position 86 region. Sequencing this sample revealed a His86. 
Discussion 
     In this paper, a real-time PCR method is described which accurately ascertains parasite 
pfmdr1 genotype. This method has high sensitivity (94%) and specificity (100%) for 
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detecting four pfmdr1 SNPs associated with drug resistance. There was 21% discordance in 
the real-time PCR genotype results between DNA samples obtained directly from patient 
blood and DNA samples obtained from subsequent in vitro cultures. 
     Real-time PCR offers several advantages over standard PCR methods for genotyping 
DNA. First, because of the small sample volume, costs for real-time PCR are much lower 
than for standard PCR. Second, using real-time PCR, a single technician can perform and 
analyze hundreds of reactions per day, thus reducing the labor cost as well. Third, this 
method reduces the opportunity for post-PCR contamination. Once the sample is prepared 
with the reagents, amplification and analysis are completed in a closed-tube system. Finally, 
real-time PCR analysis of genotype is easier and requires less scientific expertise for 
analysis. Thus, the initial cost of a real-time PCR instrument (~$40,000) would be offset by 
savings in labor, quality assurance, and materials in labs analyzing large numbers of samples. 
     In this paper, a novel 86His mutation was identified in one post-culture DNA sample. To 
our knowledge, this mutation has never been identified before and may or may not be 
associated with drug resistance. Further studies on this mutation are needed to determine if 
this mutation exists in additional parasite DNA samples using a probe specific for the 86His 
mutation.  In this instance, the mutation may have been selected for when parasites were 
cultured and was not correlated with recrudescence.      
     A previous study utilized a novel real-time PCR technology to identify pfmdr1 SNPs in 
parasite DNA extracted from clinical blood samples (39). Although the chemistry of the 
assay differed from the technique described here, both studies yielded similar results and 
concluded that real-time PCR may accurately detect Asn86 → Tyr86, Tyr184 → Phe184, Ser1034 
→ Cys1034 and Asn1042 → Asp1042 in pfmdr1. In addition, de Monbrison, et al., used this 
 36 
method to genotype Asp1246 → Tyr1246. SNPs at 1246 were not studied here because they 
have not been found in South-east Asia (114, 118).   
     Twenty-one percent of samples manifested differences in pfmdr1 genotype pre- and post-
culture. Since most patients are probably infected with a mixture of strains, the genotypes 
observed post-culture reflects the results of the selection of a subset of strains by in vitro 
culture conditions. This could manifest itself as loss of strains observed pre-culture or the 
appearance of strains not observed pre-culture because they were present at levels below 
detection limits. A much greater change in genotype (74.5%) was observed in a previous 
study looking at variations in the polymorphic regions of merozoite surface protein 1 and 
merozoite surface protein 2 as well as GLURP (glutamate-rich protein) (159), perhaps 
because these genes are more variable. 
     In addition to SNP detection, our group has previously described a real-time PCR method 
to measure pfmdr1 gene amplification (114). Thus it is now possible to assess both pfmdr1 
gene copy number and SNPs using real-time PCR making it possible to carry out a complete 
assessment of pfmdr1 genetics in large cohorts. 
     In conclusion, real-time PCR is a sensitive and specific method to detect pfmdr1 
mutations associated with antimalarial drug resistance directly from patient blood. Our 
studies suggest genotypic changes occur when patient isolates are cultured.  The resulting 
genotype is not necessarily reflective of parasite populations in vivo and drug sensitivity 
determined from parasites following a period of in vitro culture should be evaluated with 
caution.  Because it is inexpensive and amenable to high-throughput, it could be a useful 
public health tool for drug resistance surveillance and to predict treatment failure in patients. 
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Figure 2.1:  Schematic representation showing sources of samples used in study.  Of all 
the samples that amplified with real time PCR, we had 68 pairs of pre- and post-culture DNA 
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Table 2.1:  Primers and probes used in real time PCR assay   
Pfmdr1   Oligonucleotide (5'-->3') Tm*** 
86 F TGTATGTGCTGTATTATCAGGAGGAAC 63.1 
 R AATTGTACTAAACCTATAGATACTAATGATAATATTATAGG 61.7 
 Asn (wt*) probe 6FAM-ACCTAAATTCATGTTCTTT-MGB-NFQ 66.5 
  
Tyr (mut**) 
probe VIC-ACCTAAATACATGTTCTTT-MGB-NFQ 65.8 
184 F AAGATGGACAATTTCATGATAATAATCCT 59 
 R AATACATAAAGTCAAACGTGCATTTTTTA 57.6 
 Tyr (wt) probe 6FAM-CTTTTTAGGTTTATATATTTGGT-MGB-NFQ 65.2 
  Phe (mut) probe VIC-CTTTTTAGGTTTATTTATTTGGT-MGB-NFQ 65.9 
1034 F AAAAAGAAGAATTATTGTAAATGCAGCTT 57.6 
 R GGATCCAAACCAATAGGCAAAA 58.9 
 Ser (wt) probe 6FAM-ATTCAGTCAAAGCGCT-MGB-NFQ 65.8 
  Cys (mut) probe VIC-ATTCTGTCAAAGCGCT-MGB-NFQ 66.7 
1042 F AAAAAGAAGAATTATTGTAAATGCAGCTT 57.6 
 R TTTCCAGCATAACTACCAGTAAATATAAAAG 60.7 
 Asn (wt) probe 6FAM-CAATTATTTATTAATAGTTTTGC-MGB-NFQ 65.3 
 Asp (mut) probe VIC-AATTATTTATTGATAGTTTTGC-MGB-NFQ 64.8 
 
 
 
*     Wild type (Asn86, Tyr184, Ser1034 or Asn1042) sequence 
**   Mutant (Tyr86, Phe184, Cys1034 or Asp1042) sequence 
*** Melting temperature estimated by Primer Express v2.0  
For probes, the reporter dye is covalently attached at the 5’end (6FAM or VIC) with a minor 
groove binder (MGB) and non-fluorescent quencher (NFQ) covalently attached at the 3’ end.   
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Figure 2.2:  Fluorescence intensity (Rn) of the FAM reporter dye (blue line) compared 
to VIC reporter dye (green line) as PCR amplification cycles proceed (x axes).  
Fluorescent intensity is measured as Rn (y-axes), the absolute fluorescence of the reporter 
dye divided by that of the passive reference dye, Rox.  An increase in FAM indicates a wild 
type population [86(e), 184(f), 1034(g), 1042(h)] while an increase in VIC indicates a mutant 
population [86(a), 184(b), 1034(c), 1042(d)].  Mixed infections may be identified by an 
increase in fluorescent intensity of both reporter dyes (not shown).   Mutant 1034 DNA (c) 
was obtained from a previous study (114) because none of the samples in this study 
contained that mutation.  
 
 
 
a
0
500
1000
1 5 9 13 17 21 25 29 33 37
b
0
1000
2000
3000
1 5 9 13 17 21 25 29 33 37
g
0
1000
2000
3000
1 5 9 13 17 21 25 29 33 37
d
0
500
1000
1500
1 5 9 13 17 21 25 29 33 37
e
0
500
1000
1500
1 5 9 13 17 21 25 29 33 37
f
0
500
1000
1500
1 5 9 13 17 21 25 29 33 37
h
0
500
1000
1500
1 5 9 13 17 21 25 29 33 37
c
0
1000
2000
3000
1 5 9 13 17 21 25 29 33 37
 40 
 
Table 2.2:  Prevalence of mutations in monoclonal culture samples (n=20) of mutations 
detected by traditional PCR and sequencing (gold standard) and real-time PCR, and 
sensitivity and specificity of real-time PCR assay.  
 
 
 
 
 
 
 Prevalence Real Time PCR 
 PCR 
Real Time 
PCR Sensitivity Specificity 
Tyr86 5% 5%   1/1   (100%) 
19/19 
(100%) 
Phe184 65% 60% 12/13 (92%) 
  7/7   
(100%) 
Cys1034 0% 0%   0/0   (--) 
20/20 
(100%) 
Asp1042 10% 10%   2/2   (100%) 
18/18 
(100%) 
All mutations correct -- -- 15/16 (94%) 
64/64 
(100%) 
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Table 2.3:  Genotype results of pre-culture and post-culture DNA by real time PCR 
 
   Post-Culture Genotype Results 
 Codon  86 184 1042 
   
Amino 
Acid Asn Tyr His Tyr 
Tyr 
& 
Phe Phe Asn 
Asn 
& 
Asp Asp 
Asn 64 -- *1         
Tyr 1 2 --         86 
His --- -- --             
Tyr     27 1 2    
Tyr & Phe      2 4 2    184 
Phe       3 -- 27       
Asn          60 -- 3 
Asn & 
Asp           1 -- 1 
Pre-
Culture  
Genotype 
Results 
1042 
Asp             -- -- 3 
 
* Result from standard PCR and sequencing following inconclusive real time PCR results 
Data for codon 1034 was omitted because no mutant or polyclonal infections were detected in the 68 
paired samples. 
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Table 2.4:  Prevalence of mutations in patient blood (gold standard) and post-culture 
samples and sensitivity and specificity of PCR on culture-derived parasites. 
 
 
 
Note 
n=68 
a
 displayed as percentage 
b
 pre-culture DNA 
c
 post-culture DNA 
d mutations found at a single codon position 
emutations found at multiple codon positions 
 
 
 Prevalencea Culture 
Genotype Bloodb Culturec Sensitivity Specificity 
Tyr86 4 2 2/3 (67%) 65/65 (100%) 
Phe184 56 53 33/38 (87%) 27/30 (90%) 
Cys1034 0 0 0/0 (--) 68/68 (100%) 
Asp1042 7 10 4/5 (80%) 60/63 (95%) 
1 mutation per sampled 53 47 -- -- 
2 mutations per samplee 7 10 -- -- 
All mutations correct -- -- 39/46 (85%) 225/231 (97%) 
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CHAPTER 3 
Target and Mechanism of Action for DB75, [2,5-bis(4-amidinophenyl)furan], in  
Plasmodium falciparum 
 
Introduction 
     Resistance to classical antimalarials exists throughout the developing world (172).  Most 
of the current antimalarials belong to a few classes of compounds for which cross-resistance 
exists.  New antimalarials with unique targets are needed to overcome cross resistance.            
     Pentamidine, [1,5-di(4-amidinophenoxy)pentane], a dicationic diamidine, has been used 
for clinical treatment of protozoan infections such as leishmaniasis and Human African 
trypanosomiasis (HAT) (165).  It also has activity against Plasmodium falciparum; however, 
the drug is not orally bioavailable and has considerable side effects, including renal toxicity 
and cardiotoxicity (5, 21, 52).  Therefore, it has been passed over as a potential malaria 
therapeutic in favor of drugs with oral bioavailability and fewer side effects (21).  New 
pentamidine structural analogues under consideration as an alternative treatment for HAT 
represent a class of broad-spectrum antimicrobials with orally active prodrugs lacking the 
side effects associated with pentamidine (13, 122).  The aromatic diamidines inspired by 
pentamidine are being investigated for therapeutic use with HAT, malaria, Pneumocystis 
jiroveci pneumonia (PCP) and leishmaniasis (13, 165). 
     The dicationic diamidine, DB75, [2,5-bis(4-amidinophenyl)furan], is a structural analogue 
of pentamidine with antimicrobial activity, but it lacks oral bioavailability (11, 13, 19).  
DB289, [2,5-bis(4-amidinophenyl)furan bis-O-methylamidoxime], is the orally active pro-
drug of DB75 (18, 122, 178).  In a clinical trial of Thai patients with falciparum malaria, 
DB289 monotherapy (100mg, twice daily for 5 days) exhibited a 96% (22 of 23) cure rate 
(178).  In addition to its activity against Plasmodium species, DB289 is active against early 
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stage HAT and PCP, and it is currently in Phase III clinical trials for treatment of these 
infections (personal communication, Richard R. Tidwell).    
         The target and mechanism of action of diamidines against malaria are currently 
unknown but several possible mechanisms have been proposed.  First, Stead et al. showed 
that pentamidine is found in the food vacuole of P. falciparum where it binds toxic heme and 
inhibits formation of non-toxic hemozoin (147).  Second, DNA-containing organelles are 
also potential targets.  In Trypanosoma brucei gambiense, DB75 localizes in DNA-containing 
organelles, such as the nucleus and kinetoplast (86, 97).  Further, nucleic acid-binding is 
believed to inhibit topoisomerase II, a DNA replication enzyme, in Giardia lamblia (11, 96).  
Also, DB75 inhibits cellular respiration in the mitochondria of  Sacchharomyces cerevisiae 
and trypanosomes (personal communication, Charlotte A. Lanteri, (86)) Finally, DB75 
localizes in acidocalcisomes of trypanosomes where it may interrupt calcium homeostasis 
(97).  Plasmodium also possess acidocalcisomes that regulate calcium homeostasis in a 
manner similar to other protozoan (92).   
    The objective of this investigation is to elucidate the mechanism of action for DB75 in P. 
falciparum.  We used fluorescence co-localization to demonstrate DB75 subcellular 
localization in the nucleus.  In addition we showed that the drug exhibits stage-specific 
killing action in which ring stage parasites are more sensitive than trophozoites and 
development is delayed with DB75 exposure.  Finally, we determined the effects of DB75 on 
the expression of six developmentally regulated genes throughout the life cycle.   
Materials and Methods 
Parasite cultivation 
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     3D7 P. falciparum strain was maintained with 2% (v/v) O+ human erythrocytes (Research 
Blood Concepts, Brighton, MA) in 1640 RPMI supplemented with 25mM HEPES (Sigma), 
2mM L-glutamine (Gibco), 0.45% (w/v) glucose (Sigma), 0.05ng/ml gentamycin (Sigma), 
0.1 mM hypoxanthine and 10% (v/v) O+ human serum (Research Blood Concepts).  Cultures 
were maintained by the Trager and Jensen method in candle jars with low oxygen tension 
and incubated at 37oC (155).         
[3H]-Hypoxanthine Incorporation Assay  
     We measured [3H]-hypoxanthine incorporation into parasite DNA in the presence and 
absence of DB75 to assess parasite drug susceptibility in vitro. (41).  Parasite cultures were 
diluted to 0.7% parasitemia (percent infected red blood cells) in complete medium (without 
supplemental hypoxanthine).  Parasites were sub-cultured in 96-well flat bottom microtitre 
plates with serial dilutions of DB75 at final concentrations ranging from 1µM to 3.9nM.   
     To measure growth in 42 hours, the 96-well plates were incubated for 24 hours prior to 
addition of 0.5µCi of [3H]-hypoxanthine diluted in hypoxanthine-free complete media 
(25µl/well).  The cells were incubated for an additional 18 hours and harvested using an 
Inotech cell harvester and glass fiber filter paper (Inotech Systems International, INC.).  
Radioactivity of samples was determined in a liquid scintillation counter (Beckman-Coulter) 
(41). Background absorption of [3H]-hypoxanthine by erythrocytes was controlled for using 
uninfected erythrocytes, and maximum parasite growth was controlled for using nontreated 
parasites. 
     DB75 concentration required to inhibit 50% of parasite growth (IC50) was calculated 
using sigmoidal dose response nonlinear regression equation in GraphPad Prism® (version 
4.0).           
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Confocal microscopy 
     Asynchronous parasite-infected red blood cells were stained with fluorescent dyes for 
subcellular localization studies.  Cells were treated with MitoTracker Red CMXRos 
(Invitrogen) which is a mitochondrion-specific dye or LysoTracker® Red DND-99 
(Invitrogen), an acidophilic dye that localizes to the parasite food vacuole (74, 139).  Cells 
were also treated with Draq5™ (Axxora, LLC), a nuclear DNA dye in addition to the 
inherently fluorescent compound, DB75 (Table 3.1) (95).   
     To determine if DB75 co-localizes with MitoTracker Red, red blood cells infected with 
viable asynchronous parasites suspended in medium were incubated with 25nM MitoTracker 
Red for 30 minutes at 37oC in a candle jar.  The cells were centrifuged and resuspended in 
pre-warmed complete medium to remove the mitochondrial dye from the extracellular 
medium.  1µM DB75 was added and cells were transported to the Michael Hooker 
Microscopy facility (15 minutes) where 1µM of the DNA dye was added immediately prior 
to slide preparation.  To determine if DB75 co-localizes with LysoTracker Red, infected red 
blood cells were prepared as described above except cells were incubated with 50nM of 
LysoTracker.  
     To assess DB75 co-localization with Draq5™, 1µM DB75 was added to infected red 
blood cells suspended in medium prior to transport to the microscopy location.  1µM of the 
nuclear dye was added immediately prior to slide preparation.  
    To determine subcellular localization with short-term drug exposure, infected red blood 
cells (>5% parasitemia) were incubated with 1µM DB75 for less than four hours prior to 
microscopy.  For long term drug exposure, infected red blood cells (3% parasitemia) were 
exposed to 100nM DB75 for 24, 48 or 72 hours. Dyes for co-localization with DB75 were 
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added after the long exposure periods to determine the subcellular localization of the drug.  
To determine if DB75 remains in the parasite after extracellular drug pressure is relieved, 
parasites were exposed to DB75 for 24 hours and then washed by centrifugation and 
resuspended in drug-free pre-warmed medium.  The parasites were incubated for an 
additional 48 hours prior to microscopy.       
     For confocal microscopy, live cells were examined under a cover slip using a Leica 2SP 
Laser Scanning Confocal Microscope.  The 561nm Solid State laser was used to capture 
MitoTracker (absorbance/emission:  579nm/599nm) or LysoTracker (absorbance/emission:  
577nm/590nm); a UV laser (364nm) for DB75 (absorbance/emission 365nm/465nm) and 
Red HeNe laser to capture Draq5™ (absorbance/emission:  647nm/670nm) (Table 3.1).  A 
spectral scan was used to identify changes in the emission spectrum of DB75.  Adobe 
Photoshop (v.7.0) was used to create overlaid confocal images and to adjust dye contrast for 
publication.           
Parasite maturation assay 
     To determine the effect of DB75 on parasite maturation, parasites were synchronized at 
the ring stage with 5% sorbitol for 10 minutes, followed by 3 washes in RPMI medium (84).  
Cultures were synchronized every 48 hours for 3 consecutive life cycles prior to a 24-48 hour 
recovery period.  Infected red blood cells with synchronized ring or trophozoite parasites 
(0.3% parasitemia) were exposed to DB75 for 96 hours.  Medium for each sample was 
exchanged at 48 hours with fresh medium and DB75.  Nontreated synchronized cultures were 
used as a control.  Thin blood smears were prepared and stained with Giemsa stain at 0, 12, 
24, 36, 48, 60, 72, 84 and 96 hours post-exposure and examined with light microscopy to 
assess parasitemia and parasite morphology.  Parasitemia was determined by calculating the 
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number of parasite-infected red blood cells per at least 1000 total red blood cells.  Parasite 
morphology was examined and the number of rings, trophozoites and schizonts was assessed 
for at least 100 parasites.  Parasites with the “ring” structure and a single nucleus were 
classified as ring stage parasites.  Parasites containing a single nucleus and hemozoin were 
classified as trophozoites.  Multi-nucleated parasites with ample hemozoin were classified as 
schizonts.     
Gene expression 
     Red blood cells infected with sorbitol-synchronized rings were exposed to 100nM or 
500nM DB75 for 48 hours.  Nontreated cells were used as a control.  At 0, 6, 12, 18, 24, 36 
and 48 hours, RNA and DNA were immediately extracted from the harvested cells using the 
Allprep kit (Qiagen).  Also, blood smears were prepared for assessment of morphology and 
parasitemia at each time point.  RNA concentrations were measured using a NanoDrop 1000 
(NanoDrop Technologies).  50ng of total RNA was reverse transcribed using SuperScript® II 
(Invitrogen) with 2.2µM Pd(N)6 Random Hexamer (GE Healthcare) and 2.2µM Oligo(dT)20 
primers (Invitrogen) according to the manufacturer’s protocols.  All cDNA samples were 
diluted by a factor of 50 in sterile, RNase free water, and 5µL was subsequently used for 
Real Time PCR to measure expression in six developmentally-regulated genes.  Primers were 
designed using Primer Express v3.0 (Applied Biosystems) (Table 3.2).   
     Real Time PCR was performed using an Applied Biosystems 7300 Real-Time PCR 
System (Applied Biosystems) with Power SYBR® Green PCR Master Mix (Applied 
Biosystems).  cDNA was amplified with 40 cycles of: 95o for 15”, 55o for 30”, 72o for 30”.  
A dissociation curve for amplicon melting temperature analysis was performed immediately 
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following amplification to monitor nonspecific amplification (contamination or primer dimer 
amplification).       
     The expression of each gene relative to a constitutively expressed gene was analyzed for 
each sample (113).  Expression of six developmentally expressed genes were assessed:  
trophozoite antigen R45-like (ring stage), lactate dehydrogenase (late ring stage), DNA 
primase (trophozoite stage), isocitrate dehydrogenase (trophozoite stage), merozoite surface 
protein-1 (schizont stage), merozoite surface protein-7 (schizont stage) (Table 3.2) (20).  In 
replicates on the same reaction plate, amplification of cDNA for a developmentally-regulated 
gene was compared to that of the constitutively expressed, 18s rRNA.  The amplification 
efficiency for each primer pair was calculated based on the slope of the line representing 
cycle threshold (CT) values versus 3D7 genomic DNA concentrations from five separate 
experiments as previously described (113).  To determine the relative fold change in 
expression over time for each developmentally-regulated gene, we used the following 
equation (113):   
 
Fold Change in Gene Expression== (Ei)^(CTi,t – CTi,t=0) 
     (Eref)^(CTref, t – CTref, t=0)   
  
Where E is primer efficiency, CT is the cycle threshold, i is the developmentally-regulated 
gene of interest, t is the time of drug exposure, t=0 is the start of the experiment and ref is the 
18s rRNA reference gene (113).  This method accounts for variations in cDNA 
concentrations and differences in primer efficiency.  Data were graphed using GraphPad 
Prism® (v.4.03).  Results are representative of 2 separate experiments.   
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Results 
DB75 inhibits P. falciparum growth 
     To determine the antimalarial activity of DB75 in vitro, we measured tritiated 
hypoxanthine incorporation.  DB75 exhibits mean±SEM IC50 values of 124nM±10 with 
asynchronous parasites exposed for 42 hours (Figure 3.1).  When synchronized ring and 
trophozoite cultures were exposed to DB75 for 36 hours, the mean±SEM IC50 for rings was 
143±8 compared to 711±32 for exposed trophozoites, suggesting DB75 has stage specific 
activity where rings are more sensitive (Figure 3.1).  The mean±SEM IC50 was reduced to 
1.5nM±0.2 for synchronized rings exposed for 96 hours, suggesting longer incubations 
increase DB75 inhibitory activity (Figure 3.1).  
Fluorescent localization of DB75 in P. falciparum 
     We utilized the intrinsic fluorescent properties of DB75 to determine its potential 
subcellular localization in P. falciparum using confocal microscopy.  To identify possible 
sub-cellular targets, we incubated infected red blood cells with DB75 and different organelle-
specific dyes as described in the methods (74, 95, 139). In parasites exposed to 100nM or up 
to 1µM drug for less than four hours, DB75 co-localized only with Draq5™, the nuclear 
DNA stain.  Nuclear co-localization was evident in all parasite life stages except the ring 
stage with short-term exposure (Figure 3.2), suggesting that the drug initially localizes in the 
nucleus and may require a stage-specific uptake mechanism that prevents accumulation in 
ring stage parasites.  DB75 had a distinct and separate staining pattern from the red-
fluorescing LysoTracker or MitoTracker, suggesting that DB75 does not co-localize with 
these dyes in the food vacuole or mitochondrion immediately after drug exposure.  3-D 
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compilations of z-series images confirmed DB75 co-localized only with Draq5™ and not 
LysoTracker or MitoTracker (data not shown).   
     To determine if DB75 localizes to other subcellular compartments over time, 
asynchronous parasites were exposed to a therapeutic concentration (100nM) of DB75 for 
24, 48 or 72 hours.  Despite the longer incubation, DB75 co-localized only with Draq5™ 
following 24, 48 or 72 hours, suggesting the drug targets the nucleus of the parasites with 
extended exposures (Figure 3.3).  DB75 co-localization with Draq5™ was noted in all life 
stages after 24 hours of exposure, including rings.  Although DB75 was not evident in ring 
stage parasites with short-term drug exposure, the presence of DB75 in rings after extended 
drug exposure suggests DB75 may not be transported into the cell during the early part of the 
life stage.  However, with extended exposure DB75 localization in the nucleus of schizonts 
likely persists as the host cell ruptures and merozoites invade uninfected erythrocytes and 
mature to the ring stage.     
     After 48 or 72 hours of continuous exposure of infected red blood cells to 100nM DB75, 
the drug’s emission spectrum undergoes a shift from 465nm (blue) to 558nm (yellow), 
although still localized to the nucleus (Figure 3.4). This spectral shift may be the result of 
high concentrations of the compound, as is seen with the DNA-binding dye, Hoechst (112).  
A similar shift from blue to yellow fluorescence is also observed by epifluorescence in 
trypanosomes exposed to 7.5µM DB75 (97).   
     To determine if and where DB75 persists in the cell after drug pressure was removed, live 
cells were assessed with co-localization dyes 48 hours after drug was removed.  When P. 
falciparum cells were washed after 24 hours of continuous exposure to 100nM DB75, the 
blue DB75 fluorescence was still observed in the nucleus of cells at 48 and 72 hours post-
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exposure by colocalization with Draq5™.  However, only the blue fluorescence (465nm 
emission) was detected (Figure 3.3). This suggests that the drug remains in the nucleus, 
perhaps bound to DNA, but does not accumulate to high levels that may result in the 
fluorescence shift from blue to yellow.       
     With 72 hours of continuous DB75 exposure, the nontreated control parasites were 
healthy at all life stages observed by both confocal and light microscopy (data not shown). 
However, all DB75-treated parasites appeared to be unhealthy or dead following 72 hours of 
continuous exposure to 100nM DB75 (Figure 3.4).  Many treated parasites were outside of 
the host red blood cells, and all exhibited condensed nuclei.  Extracellular and pycnotic 
parasites were also observed by light microscopy using Giemsa stained blood smears (data 
not shown).   
DB75 is stage specific  
     To determine the stage-specific effect of DB75 on parasite maturation and morphology, 
we examined parasite growth and morphological changes over two full life cycles when 
either ring or trophozoites were initially exposed to drug.  Parasite maturation and survival 
time was dependent on parasite life stages at the time of initial exposure; rings were more 
sensitive to DB75 than trophozoites.  This observation was consistent with growth assays 
using synchronized infected red blood cells (Figure 3.1).   
     Our results show that nontreated cells progressed through the 48-hour life cycle as 
expected (Figure 3.5a and c).  When exposed to DB75 as rings, the parasites matured with 
the trophozoite population peaking at 24 hours after exposure (Figure 3.5a).  A subsequent 
population of schizonts peaked at 36 hours and is followed by an increase in parasitemia and 
a new ring population, initiating the second life cycle.  The ring population peaked at 60 
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hours post-exposure, followed by a trophozoite population at 72 hours and schizonts at 96 
hours. 
     Like the nontreated rings, the nontreated trophozoites also progressed through two life 
cycles as expected (Figure 3.5c).  In completion of the initial life cycle, the trophozoite 
population progressed to schizonts, which peaked at 12 hours.  The schizonts ruptured, 
increasing the parasitemia and initiating another life cycle with the first ring population.  The 
ring population peaked at 24 hours, and progressed to trophozoites which peaked at 48 hours.  
The schizont population peaked shortly thereafter at 60 hours, and in the next life cycle the 
parasitemia rose again with the appearance of a second ring population.  The second ring 
population peaked at 84 hours and progressed to trophozoites then schizonts by 96 hours.     
     However, when parasite-infected red blood cells were exposed to DB75 for 96 hours, a 
stage-specific delay in maturation was observed.  In both exposed rings and trophozoites, 
there was no change in the timing of the first ring populations compared to nontreated cells 
(Figures 3.5).  In exposed rings, the first ring population persisted until 24 hours (Figure 
3.5b); and in exposed trophozoites, the first ring population appeared at 24 hours after 
exposure (Figure 3.5d).  However, there were differences in the first trophozoite population.  
In treated exposed rings, the trophozoites peaked at 24 hours (same as nontreated cells), but 
the population persisted with a slow decline, suggesting the parasite maturation was delayed 
at this stage (Figures 3.5a and b).  In treated exposed trophozoites, the fist trophozoite 
population is almost identical to that of the nontreated trophozoites (Figures 3.5c and d).   
     The delayed maturation was also evident in the first schizont populations of DB75-
exposed ring- and trophozoite-infected red blood cells.  In treated exposed rings, the first 
schizont population was diminished and peaked at 48 hours instead of 36 (Figure 3.b).  The 
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inhibition and delay were absent in exposed trophozoites for the first schizont population 
peaks at 12 hours for both treated and nontreated cells (Figure 3.5d). 
     The appearance of the second ring population in both drug-exposed ring- and trophozoite-
infected red blood cells was practically absent, suggesting the drug prevents the initiation of 
a second complete life cycle.  This is evident by the parasitemia, which did not increase after 
the first ring population is exposed to drug (Figure 3.5b), further suggesting the parasites 
must be exposed to DB75 during the ring stage for delayed maturation during the trophozoite 
stage.  Consequently, the second trophozoite population in exposed trophozoite-infected red 
blood cells peaked 12 hours after the nontreated cells, and exhibited a slow progression to 
schizonts as observed with the first trophozoite population in exposed rings (Figure 3.5d).  
Taken together, these results suggest ring-stage parasites are more sensitive than trophozoites 
and a stall in maturation occurs after the first ring population is exposed to DB75.        
     To determine if the inhibitory effects of DB75 were reversible, infected red blood cells 
were exposed to drug for 48 hours, and then the drug was removed by washing, and cells 
were incubated for an additional 48 hours without drug.  For infected red blood cells exposed 
to 100nM DB75, parasitemia levels did not increase during the 48 hours after DB75 was 
removed (Figure 3.7).  At 48 hours the parasitemia±SD for 100nM treated rings was 
0.13±0.6%.  48 hours after drug pressure was removed, the parasitemia±SD was 0.10±0%.  
Rings exposed for 96 hours exhibited a similar growth pattern as the cells with drug removed 
(Figures 3.6a and 3.7a).  Removal of drug at 48 hours also had no effect on the sensitivity 
(Figures 3.6b and 3.7b).  These data suggest that the inhibitory effects of DB75 are 
irreversible after 48 hours.   
DB75 effect on gene transcription 
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     We measured the effect of drug on transcription for six developmentally regulated genes 
(Table 3.2) (20).   With synchronized ring-stage parasites, we assessed the transcription 
profiles for alterations in genes expressed during specific life stages relative to a 
constitutively-expressed gene.   
     For genes normally expressed during the early life stages, trophozoite antigen R45-like 
and lactate dehydrogenase, peak expression occurred in the first 12 hours following invasion 
for untreated rings (Figure 3.8a). A similar pattern was observed for cells exposed to 100nM 
or 500nM DB75 (peak expression, 12 hours).  The fold change in expression (peak intensity) 
relative to 18s rRNA for these early transcribed genes varied little with DB75 exposure.  The 
peak intensity in nontreated cells was 2.0 for lactate dehydrogenase and 2.2 or 1.7 with 
addition of 100nM or 500nM DB75, respectively (Figure 3.8b).  Similarly, peak intensity for 
trophozoite antigen R45-like was 1.0 for both nontreated and treated cells.  The DB75 
treatment had little or no effect on the timing or intensity of expression of these early genes.       
     The effects of DB75 were also measured for two trophozoite-specific transcripts:  
isocitrate dehydrogenase or DNA primase.  Peak expression for these genes in untreated 
rings occurred later than expected at 36 and 48 hours, respectively (Figure 3.8a).  Unlike the 
ring-stage genes, peak expression for the trophozoite-specific transcripts was altered with 
addition of drug.  With 100nM DB75, the expression of isocitrate dehydrogenase occurred in 
exposed rings at 30 hours post-invasion which is 6 hours earlier than nontreated cells (Figure 
3.8a).  The highest concentration of DB75 had the opposite effect.  Peak expression was 
delayed 6 hours to 42 hours post-invasion.  500nM DB75 also delayed expression of DNA 
primase by 12 hours relative to nontreated cells (60 hours).  The delays observed with the 
highest concentration of DB75 were consistent with the delay in maturation.   
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     The intensity of peak expression for both isocitrate dehydrogenase and DNA primase with 
500nM DB75 was increased (Figure 3.8b).  This is especially evident for DNA primase 
where there was a 61-fold increase in expression in nontreated cells but 192-fold increase 
with addition of 500nM DB75.  A similar trend was observed with exposure to 5nM 
atovaquone (data not shown), suggesting that the increased DNA primase expression may be 
a nonspecific response to drug or cell death rather than a specific response to DB75.  The 
lower concentration of DB75 did not have a pronounced effect on peak intensity for either 
isocitrate dehydrogenase or DNA primase (57-fold) compared to non-treated cells (Figure 
3.8b).  Thus, the expression of the trophozoite-stage genes are both delayed and increased by 
500nM drug.   
     We also measured the effect of drug on genes expressed during the schizont stage, 
merozoite surface protein-1 and merozoite surface protein-7.  For nontreated ring stage cells, 
peak expression occurred at 48 hours post invasion, when parasites were at the schizont 
stage.  There was no change in merozoite surface protein-7 peak expression time with 
100nM DB75 (48 hours) (Figure 3.8a).  However, the same concentration of DB75 delayed 
peak expression of merozoite surface protein-1.  Additionally, 500nM DB75 delayed the 
expression of both schizont-stage genes by 6 or 12 hours.  Also, 500nM DB75 drastically 
reduced peak intensity of these late-stage genes.  Merozoite surface protein-1 expression was 
reduced from a 139-fold increase to 0.7 (Figure 3.8c).  Merozoite surface protein-7 peak 
expression intensity was reduced from a 6.8 fold increase to 1.1.  Again, this is consistent 
with the delayed maturation effect observed above.   
     We also determined the effect on developmental gene expression using DB75-exposed 
synchronized trophozoites (data not shown).  Similar to exposed-rings, the expression of 
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mid- and late-stage expressed genes was delayed with 500nM DB75.  The exception to this 
was isocitrate dehydrogenase, for which peak expression was 36 hours post-invasion for 
both DB75-treated and untreated cells.  Unlike like the drug-exposed rings, peak intensity for 
late-stage genes, merozoite surface protein-1 and merozoite surface protein-7, was not 
diminished but similar to nontreated parasites.  However, peak intensity of DNA primase was 
increased from 39-fold in nontreated cells to 171-fold with 500nM DB75.    
     Taken together, DB75 does not appear to enhance or suppress selected genes whose 
expression is associated with specific lifecycle stages.  However, delays in peak expression 
for mid- and late-stage expressed genes were observed, and are consistent with the delays 
observed by microscopy.  
Discussion 
DB75 is representative of a class of newly synthesized diamidine compounds with 
antimalarial activity.  Confocal microscopy demonstrates that DB75 co-localizes with a 
nuclear DNA dye in the nucleus after both short (<4 hours) and long exposures (24-72 hours) 
but not with markers for other organelles, suggesting that DB75 may target the nucleus.  The 
absence of co-localized staining with dyes for the mitochondrion or food vacuole argues 
against these organelles as targets for DB75; however, due to the complicated nature of 
fluorescence in the cell, these organelles cannot be completely excluded.   
Tritiated hypoxanthine growth assays, in combination with the assessment of 
morphologies, suggest that ring stage parasites are more sensitive to DB75 than trophozoites, 
and exposed rings tend to stall in the trophozoite stage.  Thus, DB75 may act on the nucleus 
to affect nucleic acid synthesis or nuclear function occurring during the trophozoite stage.  
By quantifying transcription of six stage specific genes, we found that DB75 causes delays in 
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expression but not inhibition of stage-specific transcripts.  
     Previous reports suggest that the nucleus may be a target for DB75.  Epifluorescence and 
confocal microscopy studies show DB75 localizes to the nucleus and mitochondria of tumor 
cells (85, 97).  Additional studies show DB75 binds to the  minor groove of DNA at 5’-
AATT-3’ (98).  Since the nuclear genome of P. falciparum is 80% AT rich, we would expect 
the genome to contain a high number of DB75 binding sites (57).  Our results are consistent 
with these observations and show DB75 selective accumulation in the nucleus of P. 
falciparum.      
     Our data suggest that DB75 has a different mechanism of action in malaria than in 
trypanosomes.  In trypanosomes, epifluorescence experiments show that DB75 accumulates 
in the mitochondria, acidocalcisomes, nucleus, and kinetoplast (Charlotte Lanteri, personal 
communication and (96)).  Based on these observations, we expected to see accumulation in 
the nucleus, mitochondrion and/or acidocalcisomes of Plasmodium.  However, our results 
suggest that subcellular localization of DB75 is limited to the nucleus of the P. falciparum 
parasite.  While we cannot eliminate other subcellular targets based solely on DB75 
fluorescence, data from Akhil Vaidya’s lab are consistent with the observation that DB75 
does not affect malarial mitochondria (Akhil Vaidya, personal communication).  Further 
molecular studies may eliminate non-nuclear targets.     
     Our data are not consistent with the mechanism of action for diamidines proposed by 
Stead et al., who suggest that diamidine compounds act by targeting the hemozoin synthesis 
pathway in the food vacuole (147).  In solution, 3µM pentamidine binds heme and prevents 
hemozoin formation as determined by spectroscopy.  With confocal microscopy, we show 
that DB75 does not accumulate in the food vacuole with short term or long term drug 
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exposure.  One possible explanation for this lack of appearance of drug in the food vacuole is 
fluorescent quenching at low pH.  However, DB75 fluorescence is not quenched by low pH 
(J. Ed Hall, personal communication).  Further studies using electron micrographs or isotope-
labeled DB75 are needed to definitively rule out the food vacuole as a target.         
     We report here that DB75 inhibits parasite growth in a stage-specific manner that requires 
drug exposure during the ring stage.  Since DB75 is a DNA-binding compound that localizes 
in the nucleus, we expected stage-specific inhibition to correlate with nuclear activity, which 
peaks during the late trophozoite and schizont stages (20, 60, 89).  This same apparent 
paradox was observed for the polymerase-α inhibitor, aphidicolin, which is more effective  
against ring stage parasites and blocks trophozoite development (70).   
     We hypothesized that the stage-specific effect of DB75 may be explained, in part, by 
inhibition of genes transcribed early in the life cycle when DB75 exposure appears to be 
critical.  Stage-specific inhibition is also observed with the antimalarial compound, 
hexadecyltrimethylammonium bromide, which inhibits late-stage expression of Plasmodium 
falciparum choline kinase (pfck) (28).  Late stage parasites are more sensitive to 
hexadecyltrimethylammonium bromide than early ring stage parasites (28).  We expected to 
see a similar effect with DB75 inhibition of early stage transcripts to explain the stage-
specific action of DB75 and increased sensitivity of ring stages.  However, our data show 
that DB75 does not inhibit early stage transcripts at therapeutic concentrations.  Since we 
tested only 6 stage-specific genes, it is possible that DB75 may exert some specific effect on 
genes not tested.  A full microarray analysis may identify such specificity if it exists in P. 
falciparum.   
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     The increased DNA primase expression was unexpected.  A less pronounced increase was 
also observed when cells were treated with atovaquone (5nM, data not shown), suggesting 
the effect may not be drug specific, but a general response to cell death, since atovaquone 
targets the mitochondria.  DNA primase is required for DNA synthesis (26) and further 
studies are needed to determine how increased DNA primase expression is related to the drug 
mechanism of action.  DNA primase translational regulation should also be investigated 
since DB75 binds to single stranded RNA and could affect post-transcriptional modification 
or translation (179).      
     This study has few limitations.  First, synchronization of parasites is imperfect.  Parasites 
are synchronized at the ring stage and examination of morphology shows >90% of the 
parasite population is at the desired state at the start of experiments.  The remaining 
unsynchronized parasites may slightly skew gene expression and morphology results.  
Second, classification by morphology of parasite life stage is only approximate and 
imperfect.  To minimize this, the samples were blinded to prevent bias and all morphology 
assessments were determined by one individual. Third, we have shown DB75 localizes in the 
nucleus, but we cannot definitively say that this is the single target in P. falciparum.  DB75 
may exhibit unknown fluorescent properties, such as quenching, in the presence of biological 
substrates.  Therefore, we cannot conclude that the compound is not present when the 
fluorescence may, in fact, be quenched.  Finally, the complicated nature of capturing images 
of live parasite-infected erythrocytes with confocal microscopy limited the number of cells 
we were able to examine.        
     Taken together, our data suggest a mechanism for DB75 involving nucleic acid synthesis.  
We propose that the nucleus is the target of DB75.  DB75 localizes in the nucleus and slows 
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the maturation of parasites.  This is evident by the stall in development at the trophozoite 
stage.  In addition, DB75 must be present in the early life stages to interrupt nuclear activity 
in the cell.  Inhibition of developmental gene transcription is not likely to be the mechanism 
of action because alterations with gene expression profiles occur only with the highest 
concentration of DB75 and appear to be a result of the stall in maturation.  However, this 
study only examined DB75’s effect on the transcription of six select genes; future studies 
should investigate the full extent of the drug’s effect on developmental gene expression using 
microarrays.  In addition, the effect of DB75 on DNA synthesis, nuclear enzyme activity and 
mRNA translation should be examined to further elucidate the mechanism of action.  This is 
the first time the mechanism for antimalarial action of DB75 has been evaluated.  Results 
obtained in this study are potentially relevant to the clinical application of DB289.  Also, 
these results may translate to other dicationic diamidine compounds in development for 
antimalarial use.        
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Table 3.1  Subcellular localization dyes used for confocal microscopy  
Dye Target Organelle Preparation Absorbance Emission Laser 
MitoTracker Mitochondrion 25nM for 30 minutes 579nm 599nm 561nm Solid State 
LysoTracker Food Vacuole 50nM for 30 minutes 577nm 590nm 561nm Solid State 
Draq5™ Nucleus 1M 647nm 670nm 633nm HeNe 
DB75 ???? 100nM-1M 365nm 465nm 364nm UV 
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Reverse Primer  (5’-3’) 
CATTTAAGTCTGTCTTCATTCTACTTCT 
 
TCTCTATTCCATTCTTTGTCACTCTTC 
TTTTCTCCCTTTTGATAAGCTCTA 
GTTGTCTTCCCCAATGTTTTAA 
TGAAATGTCGATTCTCCTCCTT 
TTGTTACCGTTGTTGTGTGTCCTA 
GGGTAGGAGTACTCATAATATGTAGA 
Forward Primer  (5’-3’) 
ACGAGCTGACCCACCAAA 
 
ACGATTTGGCTGGAGCAGAT 
CCAGACGGTGTTACGTGTGT 
 
AGATTGTCTCCTCAAAACCTTTATAG 
CAAAGTGAAACAGATACTCAATCTAAAA 
AGCAAGCGAAACAACTGAAGA 
GGCAACTGTTATATGTAAACAAGCA 
Stage  
Expressed 
Ring 
Late Ring/ 
Early 
Trophozoite 
Trophozoite 
Trophozoite 
Schizont 
Schizont 
Constitutive 
*Maximum  
Expression 
(hr)  
16 
21 
29 
 
30 
37 
42 
 
Gene  (PlasmoDB ID) 
Trophozoite Antigen r45-like 
protein (PFD1175w) 
L-lactate dehydrogenase 
(PF13_0141) 
Isocitrate dehydrogenase 
 (PF13_0242) 
DNA primase (PFI0530c) 
Merozoite surface protein 7 
(PF13_0197) 
Merozoite surface protein 1 
 (PFI1475w) 
Ribosomal protein S18 
(PF11_0272) 
*Time post-invasion for maximum transcript levels detected by microarray (20) 
Table 3.2:  Developmentally expressed genes in P. falciparum 
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Figure 3.1:  DB75 inhibition of P. falciparum.  The percent inhibition of parasite growth 
was measured with tritiated hypoxanthine for asynchronous parasites exposed to drug for 42 
hours (grey line, open circle); synchronized ring-stage parasites exposed to drug for 36 hours 
(black line, closed square); synchronized rings-stage parasites exposed to drug for 96 hours 
(black line, open square); and synchronized trophozoite-stage parasites exposed to drug for 
36 hours (black line, closed triangle). 
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Figure 3.2:  DB75 subcellular distribution in different P. falciparum life stages upon 
immediate cell entry (<4 hours).  (A) 1µM DB75 (blue) and LysoTracker Red show no co-
localization of the food vacuole of a trophozoite.  (B) In a schizont, 1µM DB75 co-localizes 
with green nuclear Draq5™ stain but not MitoTracker Red.  (C) 1µM DB75 fluorescence is 
not present in ring stage parasites.  All images are representative.   
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Figure 3.3:  DB75 subcellular distribution following long term drug exposure.  (A) 
Infected erythrocytes exposed to 100nM DB75 for 24 hours.  Note co-localization of DB75 
and nuclear DNA stain, Draq5™.  (B) Drug was removed by washing at 24 hours and 
infected erythrocytes incubated for an additional 48 hours in drug-free medium.  Note 
persistent co-localization of DB75 and Draq5™ in nucleus of pycnotic infected erythrocyte.  
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Figure 3.4:  DB75 distribution in an erythrocyte infected with multiple parasites following 
72 hours of exposure.  DB75 emits at both 465nm (b) and 558nm (c) with extended exposure. 
The fluorescence emitted at these wavelengths overlay with Draq5™ (f and g).    
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 Figure 3.5:  Parasite morphology with 96 hour continuous DB75 exposure. (a and b) 
Synchronized rings or (c and d) trophozoites (a and c) without treatment or (b and d) with 
exposure to 100nM DB75 (b and d) for 96 hours.  The number of ring (yellow), trophozoite 
(green) and schizonts (purple) are shown per 1000 red blood cell over time.  Note:  the x-axis 
of (b) is on a different scale. 
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Figure 3.6:  Parasite growth with 96 hour drug exposure.  (a) Synchronized rings or (b) 
trophozoites were exposed to various concentrations of DB75 for 96 hours.  Parasitemia was 
determined at 12 hour intervals for each DB75 drug concentration.   
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 Figure 3.7:  Parasitemia over time when DB75 drug pressure is removed after 48 hours 
of continuous exposure.  (a) Synchronized rings or (b) trophozoites were exposed to various 
concentrations of DB75 for 48 hours before cells were washed and incubated an additional 
48 hours without drug pressure.  
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Figure 3.8  Effect of DB75 on peak expression time and intensity.  Expression profiles for 
six developmentally expressed genes were compared in synchronized rings with exposure to 
100nM (grey) or 500nM (black) DB75 or left untreated (white).  (a) Time of invasion was 
approximated based on assessment of morphology, and peak expression post-invasion was 
estimated for all genes.  (b) Expression intensity at time of peak expression was measured as 
the fold change in expression relative to the constitutively expressed 18s rRNA for exposed 
rings.  Genes evaluated include:  trophozoite antigen r45-like (Troph Ag); lactate 
dehydrogenase (ldh), isocitrate dehydrogenase (Iso); DNA  primase (DNAp), Merozoite 
surface protein-1 (MSP-1); Merozoite surface protein-7(MSP-7).           
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DB75 interaction with other antimalarial compounds 
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PREFACE 
 
     The following chapter is in preparation for publication as a 1400-word “Notes” 
submission to Antimicrobial Agents and Chemotherapy.  This chapter is an expanded version 
of the article prepared for publication.  Contributing authors include:  Anne Purfield, Richard 
R. Tidwell and Steven R. Meshnick.  Anne Purfield is the primary author and has conducted 
all experiments and analyses.  Stephanie Wallace assisted with parasite maintenance, and 
Jesse Kwiek contributed to the experimental design.    
     This research was supported by Medicines for Malaria Venture and the Bill and Melinda 
Gates Foundation.  
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CHAPTER 4 
DB75 interaction with other antimalarial compounds 
 
Introduction 
     DB289, [2,5-bis-(4-amidinophenyl)furan bis-O-methylamidoxime], is a promising new 
orally active antimicrobial compound (178).  DB289 is the pro-drug of the active metabolite 
DB75, [2,5-bis-(4-amidinophenyl)furan], (175) which is effective against P. falciparum, 
Pneumocystis jiroveci,  Trypanosoma brucei, and Leishmania spp. in vitro and in animal 
models (22, 153).   
     DB289 has shown promising activity against both malaria and African trypanosomiasis 
infections in humans.  In a clinical study conducted in Thailand, DB289 (100 mg/day x 5 
days) cured 22 of 23 (96%)  P. falciparum-infected patients (178).  The drug was well 
tolerated in patients and exhibited a mean ±SD parasite clearance time of 43h ±41 (178) 
which is comparable to the highly efficacious combination of atovaquone and proguanil 
(41.9±22.1) (82).   
     Because P. falciparum can develop resistance to monotherapy quickly, the WHO 
recommends that all new treatment regimens be combinations of antimalarials (1). For 
partner drugs to be effective in practice, they should ideally be synergistic and certainly not 
be antagonistic.  DB289 represents a safe, effective and structurally novel compound that 
may be used in combination for treatment of P. falciparum malaria (178).   
     The aim of this study was to characterize the interactions of the active metabolite, DB75, 
with other antimalarials in order to help identify the best partner drug for combination 
therapy.  We report here that in vitro activity of DB75 was indifferent when combined with 
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10 antimalarial compounds that include:  atovaquone, artemisinin, amodiaquine, 
azithromycin, chloroquine, tafenoquine, pyronaridine, piperaquine, tetracycline and 
mefloquine.  DB75 and clindamycin appeared to act in a synergistic manner with drug 
exposures of 42 or 66 hours.  However, when cells were exposed to these drugs for 96 hours, 
the combination had an indifferent effect on parasite inhibition.   
Materials and Methods 
Parasite Culture 
     3D7 “wild type”, drug susceptible P. falciparum was maintained in O+ human 
erythrocytes (Research Blood Concepts, Brighton, MA) supplemented with 1640 RPMI with 
25mM HEPES (Sigma Aldrich, St. Louis, MO), 2mM L-glutamine (Gibco, Carlsbad, CA), 
0.45% (w/v) glucose (Sigma Aldrich, St. Louis, MO), 0.05ng/ml gentamycin (Sigma Aldrich, 
St. Louis, MO), 0.1 mM hypoxanthine and 10% O+ human serum (Research Blood 
Concepts, Brighton, MA).  Cultures were maintained at 37 oC by a modified version of the 
Trager and Jensen method in candle jars with low oxygen tension (155).         
42 hour [3H]-Hypoxanthine Incorporation Assay  
     To measure in vitro drug sensitivity, we used [3H]-hypoxanthine incorporated into 
parasite-synthesized DNA (41).  Parasite cultures were diluted to 0.7% parasitemia in 2% 
(v/v) erythrocytes and complete medium without supplemental hypoxanthine.  180µl of 
infected red blood cells were sub-cultured in 96-well flat bottom microtitre plates with 10µL 
of DB75.  DB75 was tested in combination with:  amodiaquine, artemisinin, atovaquone, 
azithromycin, chloroquine, clindamycin, mefloquine, piperaquine, pyronaridine, tafenoquine 
and tetracycline.  Atovaquone and proguanil were tested in combination as a positive control 
to validate the method.  All compounds were dissolved in water, 95% ethanol or DMSO for 
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stock solutions.  Serial dilutions were made from the stock solution in medium without 
supplemental hypoxanthine.  10µl of diluted drug was added to infected red blood cells with 
DB75 in 96-well plates.   
     To test the sensitivity of parasites to variable concentrations of two drugs in combination, 
we used a checkerboard matrix of decreasing DB75 concentrations across the plate with 
concentrations of the partner drug decreasing down the plate (41).  The drug concentration 
ranged from 5-10X above and below the IC50 (concentration for 50% of maximal growth 
inhibition) of the drug.  In addition, we tested each drug alone to control for the sensitivity in 
the absence of a partner drug in combination.  We also controlled for: 1) parasite growth in 
the absence of drug (maximum growth) and 2) erythrocyte uptake of [3H]-hypoxanthine 
(background).   
     To measure growth in 42 hours, the 96-well plates were incubated for 24 hours prior to 
the addition of 0.5µCi of [3H]-hypoxanthine diluted in hypoxanthine-free medium 
(25µl/well).  The cells were incubated for an additional 18 hours and harvested using an 
Inotech cell harvester and glass fiber filter paper (Inotech Systems International, INC.).  
Radioactivity of samples was determined in a liquid scintillation counter (Beckman-Coulter).  
For each drug combination, the assay was repeated two or three times. 
66 hour [3H]-Hypoxanthine Incorporation Assay 
     To measure growth in 66 hours, the same methods were followed as described above 
except a 0.4% parasitemia was used and [3H]-hypoxanthine was added to the 96-well plates 
following 48 hours of incubation.  The parasites were incubated for an additional 18 hours 
and harvested as described above.  DB75 was tested in combination with tetracycline, 
clindamycin, azithromycin, and tafenoquine at 66 hours for growth inhibition.    
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96 hour [3H]-Hypoxanthine Incorporation Assay 
     To measure growth in 96 hours with clindamycin, we used 0.3% sorbitol-synchronized 
ring cultures (84).  The [3H]-hypoxanthine was added to the 96-well plates following a 48 
hour incubation. Cells were incubated an additional 48 hours prior to harvesting and 
scintillation counting.  DB75 was tested in combination with clindamycin at 96 hours. 
Interpretation of Results 
     To determine the IC50 value from percent inhibition (Equation 1), we used the sigmoidal 
dose response equation (Equation 2) from the nonlinear regression analysis of Graphpad 
Prism® (version 3.0).  The maximum growth was calculated from the average count per 
minute (cpm) of 10 control wells with infected erythrocytes but no drug.  The background is 
defined as the average cpm from 10 wells with uninfected erythrocytes.     
 
Equation 1:  Percent Inhibition =   CPMi – Background     * 100                   
      Max. Growth – Background  
 
Equation 2: Y=   ____Bottom + (Top-Bottom)__ 
      (1+10(LogEC50-X)*HillSlope) 
 
Where X is the logarithm of drug concentration; Y is the percent inhibition; “Bottom” is 
minimum percent inhibition (0); and “Top” is maximum percent inhibition (100). 
     We evaluated the effect using isobolograms, fractional inhibitory concentrations (FIC) 
(Equation 3) and sum FIC values to determine the relationship between DB75 and the partner drug 
(10, 15) .   
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Equation 3:  FIC = IC50 of DB75 in combination  +  IC50 of partner drug in combination 
      IC50 of DB75 alone            IC50 of partner drug alone 
 
     For an isobologram, the IC50 values of DB75 with the partner drug at each combination 
of concentration were plotted against the IC50 values of the partner drug in combination with 
DB75 dilutions.  A line was drawn to connect the IC50 values of each drug.  If the points on 
the graph fell under the line, the interaction was determined to be synergistic.  If the points 
fell along the line, the interaction was indifferent and if the points fell above the line the 
interaction was antagonistic.   
      The FIC was used to normalize against a concentration-dependent bias.  FIC values were 
plotted as isobolograms using FIC values instead of IC50 values (Figure 4.1) (25).  A line 
was drawn between 1.0 on the x and 1.0 on the y axis.  The relationship was evaluated by the 
location of the FIC values below, above or on the line, as described above (25).      
     The mean sum FIC value was used to quantify the drugs’ effect in combination.  For the 
sum FIC of each partner drug combination, the FIC values were added together.  A value 
above 2.0 indicated antagonism while values less than 0.5 suggest synergism.  Sum FIC’s 
that fell between 0.5 and 2.0 were indicative of an indifferent relationship (10, 15, 25).     
Results 
     To find a potential partner for DB75, the compound was tested in combination with 11 
current and investigational antimalarials.  As a positive control, atovaquone and proguanil 
showed synergy in combination (sum FIC=0.63) (Figure 4.1a).  The antimalarials tested in 
combination represented six classes of compounds, including aryl amino alcohols, 4-
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aminoquinolines, 8-aminoquinolines, antimicrobials, peroxides and naphthoquinones; and all 
results are summarized in Table 4.1.        
     The structurally similar aryl amino alcohols, 4-aminoquinoline and 8-aminoquinoline 
compounds all produced an indifferent effect in combination with DB75.  The 4-
aminoquinoline compounds tested, including chloroquine, amodiaquine, pyronaridine and 
piperaquine; produced some of the highest sum FIC values of all compounds tested although 
well below values considered antagonistic (mean±SD sum FIC=1.21±0.09).  Chloroquine, in 
particular, had the highest mean±SD sum FIC at 1.31±.12 (Figure 4.1h).  The only 8-
aminoquinoline compound tested was tafenoquine, which was indifferent in combination 
with DB75 at 42 hours (mean±SD sum FIC=1.00±0.06) (Figure 4.1d).  Tafenoquine was also 
tested in combination for 66 hours because it is a long acting drug, but it was still indifferent 
with DB75 (mean±SD sum FIC=1.05±0.06) (Figure 4.2b).  Mefloquine, an aryl amino 
alcohol, was indifferent in combination with DB75 when tested for 42 hours (mean±SD sum 
FIC=1.08±.14) (Figure 4.1i).   
     The peroxides and naphthoquinones are structurally-unique antimalarials.  In combination 
with DB75, compounds from both classes had an indifferent effect on parasite growth 
(Figure 4.2g and k).  The fast-acting peroxide, artemisinin, had a mean±SD sum FIC of 
1.19±0.15.  Atovaquone, a naphthoquinone, was also indifferent in combination with DB75 
(mean±SD sum FIC=0.94±0.14).   
     The long-acting antibiotic compounds, azithromycin, clindamycin and tetracycline were 
also tested in combination with DB75 for short and extended exposures.  First, both 
azithromycin and tetracycline were indifferent when tested for 42-hour (Table 4.1 and Figure 
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4.1b and f) or 66-hour exposures (Table 4.1 and Figure 4.2a and c). However, results for the 
clindamycin-DB75 combination were less clear-cut. 
     As previously described, clindamycin alone exhibited a biphasic concentration response 
(137).  Complete inhibition was not achieved with clindamycin alone at 42- or 66-hour 
exposures even with hemolytic concentrations of more than 100µM (Figure 4.3a and b).  For 
this reason, the interaction with DB75 could not be assessed by the traditional FIC or sum 
FIC methods.  However, it was clear from the concentration response curves that 
clindamycin has an effect on the DB75 IC50 at 42 and 66 hours (Figure 4.3a and d).  
Clindamycin concentrations as low as 164nM enhanced the inhibitory effect of DB75 alone 
by nearly tenfold (Figure 4.3a and d).  Alone, DB75 exhibited an IC50 of 82nM but in 
combination with 164nM clindamycin, the IC50 of DB75 was reduced to 8.9nM.  When 
clindamycin and DB75 were incubated together for 66 hours, DB75 concentration response 
curves suggest clindamycin reduced the DB75 IC50 albeit less impressive than the effect 
seen in the 42-hour assay (Figure 4.3b).  For example, the IC50 of DB75 is reduced from 
95nM when used alone to 14nM when used in combination with 123nM clindamycin (Figure 
4.3b) 
     Since both clindamycin and DB75 have long onsets of action in vivo (59, 178), we 
determined whether the “enhancing” effect was apparent with an extended incubation period 
equal to two complete life cycles (96 hours).  By itself, DB75 is much more potent after long 
incubations than after short incubations (Table 4.2).  However, when DB75 and clindamycin 
were incubated in combination for 96 hours, a sigmoidal dose response was evident for 
clindamycin alone.  This allowed us to calculate an IC50 value to use with standard FIC 
methods for analysis.  At 96 hours the interaction was indifferent with a mean±SD sum FIC 
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of 1.10±0.16 (Figure 4.2d).   This suggests that the combination of drugs may not be 
synergistic in the classical sense, but that the combination may accelerate parasite killing 
upfront. 
Discussion 
     DB75 manifested indifferent relationships with 10 of the drugs tested in the 42-hour 
assay.  Three of these drugs (tetracycline, tafenoquine and piperaquine) also showed 
indifference even with extended incubations.  However, clindamycin reduced the DB75 IC50 
with 42 and 66-hour assays, although the effect was indifferent when DB75 and clindamycin 
were tested in combination for 96 hours.   
     The indifferent effect that DB75 had with drugs in combination may suggest an 
independent mechanism.  DB75 is known to bind the minor groove of DNA and may inhibit 
DNA replication or gene transcription (98).   Combination therapy using drugs with unique 
mechanisms was proposed to slow the development of resistance to each partner drug (169).  
Taken together, an independent mechanism and indifferent drug interactions suggest that 
DB75 could be successfully partnered with a variety of antimalarials including: amodiaquine, 
artemisinin, atovaquone, azithromycin, chloroquine, clindamycin, mefloquine, piperaquine, 
pyronaridine, tafenoquine and tetracycline.  However, the pharmacokinetic profiles of each 
drug in combination should be similar to prevent resistance from developing to partner drugs 
with longer elimination (169).  The elimination half-life of DB75 is 53 hours (Richard R. 
Tidwell, personal communication).  Of the 11 compounds tested in combination with DB75, 
two have similar elimination half-lifes:  atovaquone (50-84hr) and azithromycin (59-72hr) 
(30, 69).     
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     Our results suggest that clindamycin enhances parasite killing in combination with DB75 
for 42 or 66 hours, but not at 96 hours.  The synergy observed with shorter incubations 
suggests DB75 has a mechanism of action unique from clindamycin, although both drugs 
have long onsets of action  (24, 178).  Clindamycin is believed to target protein synthesis in 
the apicoplast of the parasite (36, 53, 123).  The apicoplast is unique to the apicomplexan 
parasites, contains an independent genome (35-kb) and is critical for parasite survival 
(reviewed in (134)).  DB75, on the other hand, possibly targets nuclear activity in P. 
falciparum, as proposed in Chapter 3 of this thesis.   
     The indifferent effect of DB75 and clindamycin at 96 hours may be a consequence of the 
drugs’ long onsets of action.  Both drugs exhibit delayed death phenotypes, in which the 
antimalarial effect occurs in the progeny of parasites exposed to drug (Chapter 3 of this 
dissertation and (24, 36).  For clindamycin, the progeny are unable to replicate apicoplasts, 
which leads to arrested development at the schizont stage and incomplete schizogeny 
(rupture of host cells and invasion of uninfected red blood cells) (36).  We proposed in 
Chapter 3 of this dissertation that the antimalarial effect of DB75 is stage-specific.  Ring-
stage parasites must be exposed to DB75, and then parasite development is delayed and 
arrested at the trophozoite stage.  When trophozoites are exposed to DB75, the same 
antimalarial effect is observed in the progeny of exposed cells.  However, both DB75 and 
clindamycin inhibit the emergence of a second- or third- generation ring population, 
depending on the drug and the development stage at time of initial exposure.  Based on the 
independent mechanisms of DB75 and clindamycin, it possible that synergy occurs between 
the drugs in the first two life cycles because the drugs have unique targets and life stages, but 
by the end of the 2nd complete life cycle both drugs have effectively eliminated parasites.   
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     Despite the synergy observed, a slow onset of action and short half life of clindamycin 
would not be ideal when paired with DB75, which has a long half life and long onset of 
action, for treatment of malaria in endemic areas.  However, this combination may provide 
effective chemoprophylaxis for malaria because neither drug has been used for malaria 
treatment to date.  Therefore, it is likely that there is no resistance to either of these drugs, 
and when used in combination for prophylaxis, resistance would be slow to emerge.  Further 
studies need to be conducted to determine the effect of clindamycin and DB75 on parasite 
morphology and growth over two complete life cycles to determine if the drugs in 
combination result in parasite death earlier in the life cycle than each drug alone.  Also, this 
combination should be tested in vivo for the therapeutic effect to treat or prevent malaria 
infection.    
     This study has few limitations.  First, only one parasite strain, 3D7, was used to test for 
the inhibitory effect of DB75 in combination with other antimalarials.  3D7 is considered a 
“wild type”, drug sensitive strain of P. falciparum.  Other strains that exhibit decreased 
susceptibility to various drugs may reflect parasite populations in malaria endemic areas.  
Second, clindamycin exhibits a biphasic killing curve in 42- and 66-hour assays.  It is 
difficult to determine the IC50 from biphasic curves, therefore the synergy of DB75 and 
clindamycin at these time points was determined from the effect of clindamycin on the DB75 
IC50 instead of the usual method based on FIC.    
     In summary, we have demonstrated the effect of DB75 in combination with 11 
antimalarial drugs.  All drugs tested with DB75 exhibited an indifferent effect on parasite 
growth except clindamycin.  Clindamycin promoted DB75 action at 42 and 66 hours but the 
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interaction was indifferent at 96 hours.  This study suggests that DB75 has an independent 
mechanism from the drugs tested, and all may be used in combination with DB75.   
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Figure 4.1:  DB75-partner drug interactions with 42-hour co-incubation at various 
concentration ratios.  (b-k) Growth was measured using [3H]-hypoxanthine growth assays 
for all drugs tested in combination with DB75.  (a) Atovaquone and proguanil were used in 
combination to show true synergy.  (a) A concave isobologram indicates synergy; a convex 
one indicates antagonism (none shown) and (b-k) points along the straight line indicate 
indifference. 
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Figure 4.2:  DB75-partner drug interaction with (a-c) 66-hour or 96-hour (d) co-
incubation.  All interactions shown are indifferent.      
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Figure 4.3:  Clindamycin effect on DB75 IC50.   Parasite inhibition was measured with 
DB75 and clindamycin co-incubated for (a) 42-hour, (b) 66-hour and (c) 96-hour.  3-fold 
serial dilutions of clindamycin (closed square) were used with a DB75 only control.  
Concentrations of clindamycin are shown to the right of each dose-response curve.  (d)  Low 
concentrations of clindamycin enhance the effect of DB75 by reducing the IC50.  
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Table 4.1:  Results for antimalarial agents in combination with DB75a 
 
a
  values are reported as means and standard deviation of 2-3 assays 
b
 Synchronized rings were used for the 96 hour assay 
S= synergistic, I-indifferent 
 42 hour Assay 66 hour Assay 96 hour Assay 
Partner Drug FIC 
Sum FIC 
(±SD) FIC 
Sum FIC 
(±SD) FIC 
Sum FIC 
(±SD) 
Clindamycin S N/A S N/A I 1.18b 
Tetracycline I 0.88 (0.08) I 1.04 (0.19)   
Atovaquone I 0.94 (0.14)     
Tafenoquine I 1.00 (0.06) I 1.05 (0.06)   
Mefloquine I 1.08 (0.14)     
Amodiaquine I 1.09 (0.03)     
Artemisinin I 1.19 (0.15)     
Piperaquine I 1.23 (0.04)     
Azithromycin I 1.20 (0.18) I 1.29 (0.13)   
Pyronaridine I 1.20 (0.02)     
Chloroquine I 1.31 (0.12)     
Atovaquone and 
Proguanil I 0.63     
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Table 4.2:  DB75 IC50 decreases with extended exposure 
 
Exposure (hr) DB75 IC50 (nM) 
42 128 ± 51 
66 139 ± 43 
96 3.7 ± 0.76 
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CHAPTER V 
Summary and Future Directions 
 
     This dissertation focuses on the mechanism of resistance and mode of action for drugs 
against P. falciparum.  With widespread existence of drug resistant parasites, there is an 
increasing need for evaluation of resistance mechanisms and new drugs to combat malaria.  
In this report, we provide a new method for monitoring drug resistance.  Also, we attempt to 
elucidate the mechanism of action for DB75, the prodrug of the antimalarial compound 
DB289.  Finally, we determine the antimalarial effect of DB75 in combination with other 
antimalarial drugs in vitro.     
     We report a new method for pfmdr1 SNP analysis allows for rapid identification of 
mutations associated with drug resistance.  Real time PCR is sensitive and specific method 
that may be used for high-throughput analysis of parasite genotypes.  Alternative methods 
require parasites to be sub-cultured for drug-susceptibility testing and analysis of genotype 
using PCR and sequencing or restriction fragment length polymorphism (RFLP).  Real time 
PCR is less labor extensive and incurs less cost per reaction than these methods.  Future 
epidemiological studies may use this method as a public health tool to survey parasite 
populations for drug resistance and to predict treatment failure in individuals.  Ultimately, 
this tool may provide insight about the temporal evolution and geographical spread of 
parasite populations exhibiting drug resistance.  With adequate surveillance data, healthcare 
officials may evaluate and, if necessary, adjust policy regarding antimalarial treatment.  
Proper action may thwart the spread of antimalarial drug resistance, prolong the use of 
treatments and ultimately, reduce mortality.   
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     There is an urgent need for new antimalarial compounds with the rapid emergence and 
spread of resistance to currently used drugs.  We report antimalarial characteristics for the 
metabolite, DB75, of the novel antimicrobial drug, DB289.  DB289 is currently in 
development for treatment of falciparum malaria, however the mode of action against 
falciparum parasites is unknown.  We propose a partial mechanism of DB75.   
     DB75 targets the nucleus of the parasite.  Our results from ultraviolet confocal 
microscopy show DB75 localization exclusively in the nucleus of parasites in culture.  
Previous reports have suggested the target may be the mitochondrion, acidocalcisome or food 
vacuole (97, 147).  However, we show DB75 only accumulates in the nucleus with short or 
long term exposure.  This is consistent with data showing DB75 binds to AT rich sequences 
of DNA (98).  To date, no other antimalarial compound has been shown to target the nucleus, 
suggesting DB75 has a unique target in P. falciparum. 
      We also propose the mechanism of action for DB75 is stage specific.  Assessment of 
parasite morphologies after DB75 exposure shows early stage parasites are more sensitive to 
drug than late stage parasites.  Parasites must be exposed during the ring stage for effective 
inhibition.  This may explain the need for a 5 day dosing regimen for effective parasite 
clearance in vivo.  Our data suggests in vivo, early stage parasites are effectively cleared in 
the first 48 hours of treatment.  However all parasites in the trophozoite or schizont stages 
must advance to the next life cycle and be exposed as rings before elimination. 
     The increased sensitivity of rings suggests the DB75 mode of action involves interruption 
of a stage-dependent process such as nucleotide synthesis.  When cells are treated with 
aphidicolin to arrest DNA synthesis a similar effect is observed (70).  Both aphidicolin and 
DB75 stall parasite maturation as well.  Aphidicolin arrests development at the late 
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trophozoite-schizont stage (70).  However, DB75 stalls maturation at the early-mid 
trophozoite stage, suggesting that an additional mechanism might be involved.  Further 
studies are needed to evaluate the effect of DB75 on other nuclear activities such as enzyme 
activity and mRNA translation.  
     We report here that the DB75 mechanism is not likely to include inhibition of 
developmental gene transcription.  The expression profiles of six developmentally expressed 
P. falciparum genes were not significantly altered with therapeutic concentrations of DB75 
(100nM).  However, a higher concentration of DB75 (500nM) altered the profiles of some 
genes in a manner consistent with delayed maturation.  We conclude that these changes 
observed in select genes are not responsible for the delay in maturation because they occur 
concurrently with the stalled cell cycle.  However, further studies are necessary using 
microarray analysis to determine the effect of DB75 on developmental regulation of all 
genes.           
     We observed a sharp increase of DNA primase expression with 500nM DB75.  Although a 
similar result was obtained with atovaquone treated cells, more extensive studies with 
atovaquone and other antimalarial drugs may determine the whether this results is drug-
specific or significant to the mechanism of DB75.   
    Taken together, our data suggests DB75 has a unique target in P. falciparum.   Our results 
are consistent with a mechanism that includes inhibition of DNA synthesis with other nuclear 
activity possible.   
     With a unique target in, DB75 is an ideal candidate combination therapy.  We show that 
DB75 is indifferent in combination with atovaquone, azithromycin, piperaquine, tafenoquine, 
pyronaridine, tetracycline, artemisinin, chloroquine, mefloquine amodiaquine and 
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atovaquone.  This is further support that DB75 has an independent target and/or mechanism 
from currently used antimalarials.  Further, our results suggest that some synergism may 
exist when DB75 is used in combination with clindamycin and additional studies need to be 
carried out to identify the extent of this interaction.  If these two drugs produce effective 
synergism, the combination may be a useful tool to combat malaria in resource poor regions 
because clindamycin is an inexpensive drug.         
     Taken together, this work contributes to the arsenal of tools for surveillance of falciparum 
malaria drug resistance and partially elucidates a mechanism of action for a novel 
antimalarial diamidine that may be used for malaria therapy.   
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